<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://hmg.oxfordjournals.org">
<title>Human Molecular Genetics - recent issues</title>
<link>http://hmg.oxfordjournals.org</link>
<description>Human Molecular Genetics - RSS feed of recent issues (covers the latest 3 issues, including the current issue) </description>
<prism:eIssn>1460-2083</prism:eIssn>
<prism:publicationName>Human Molecular Genetics</prism:publicationName>
<prism:issn>0964-6906</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP-a?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP-b?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP-c?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4467?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4478?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4492?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4501?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4513?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4521?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4530?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4546?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4552?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4565?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4576?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4590?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4603?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4615?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4629?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4640?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4650?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4662?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4669?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4677?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4688?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/NP?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/NP-a?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/NP-b?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/NP-c?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4227?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4239?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4255?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4268?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4282?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4296?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4304?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4317?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4329?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4340?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4350?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4357?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4367?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4376?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4390?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4405?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4415?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4428?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4442?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4457?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/NP?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/NP-a?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/NP-b?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/NP-c?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4013?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4022?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4035?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4046?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4054?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4066?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4081?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4089?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4102?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4118?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4130?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4141?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4153?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4171?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4180?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4189?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4195?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4204?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4213?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4219?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4226?rss=1" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP?rss=1">
<title><![CDATA[Contents Page]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:11 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp485</dc:identifier>
<dc:title><![CDATA[Contents Page]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP-a?rss=1">
<title><![CDATA[Cover Page]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP-a?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:11 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp486</dc:identifier>
<dc:title><![CDATA[Cover Page]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP-b?rss=1">
<title><![CDATA[Editorial Board]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP-b?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:11 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp487</dc:identifier>
<dc:title><![CDATA[Editorial Board]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP-c?rss=1">
<title><![CDATA[Subscription Page]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP-c?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:11 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp488</dc:identifier>
<dc:title><![CDATA[Subscription Page]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4467?rss=1">
<title><![CDATA[Ku70 regulates Bax-mediated pathogenesis in laminin-{alpha}2-deficient human muscle cells and mouse models of congenital muscular dystrophy]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4467?rss=1</link>
<description><![CDATA[
<p>The severely debilitating disease Congenital Muscular Dystrophy Type 1A (MDC1A) is caused by mutations in the gene encoding laminin-2. Bax-mediated muscle cell death is a significant contributor to the severe neuromuscular pathology seen in the <I>Lama2</I>-null mouse model of MDC1A. To extend our understanding of pathogenesis due to laminin-2-deficiency, we have now analyzed molecular mechanisms of Bax regulation in normal and laminin-2-deficient muscles and cells, including myogenic cells obtained from patients with a clinical diagnosis of MDC1A. In mouse myogenic cells, we found that, as in non-muscle cells, Bax co-immunoprecipitated with the multifunctional protein Ku70. In addition, cell permeable pentapeptides designed from Ku70, termed Bax-inhibiting peptides (BIPs), inhibited staurosporine-induced Bax translocation and cell death in mouse myogenic cells. We also found that acetylation of Ku70, which can inhibit binding to Bax and can be an indicator of increased susceptibility to cell death, was more abundant in <I>Lama2</I>-null than in normal mouse muscles. Furthermore, myotubes formed in culture from human laminin-2-deficient patient myoblasts produced high levels of activated caspase-3 when grown on poly-<scp>l</scp>-lysine, but not when grown on a laminin-2-containing substrate or when treated with BIPs. Finally, cytoplasmic Ku70 in human laminin-2-deficient myotubes was both reduced in amount and more highly acetylated than in normal myotubes. Increased susceptibility to cell death thus appears to be an intrinsic property of human laminin-2-deficient myotubes. These results identify Ku70 as a regulator of Bax-mediated pathogenesis and a therapeutic target in laminin-2-deficiency.</p>
]]></description>
<dc:creator><![CDATA[Vishnudas, V. K., Miller, J. B.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:11 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp399</dc:identifier>
<dc:title><![CDATA[Ku70 regulates Bax-mediated pathogenesis in laminin-{alpha}2-deficient human muscle cells and mouse models of congenital muscular dystrophy]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4477</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4467</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4478?rss=1">
<title><![CDATA[Lowe syndrome patient fibroblasts display Ocrl1-specific cell migration defects that cannot be rescued by the homologous Inpp5b phosphatase]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4478?rss=1</link>
<description><![CDATA[
<p>The Lowe syndrome (LS) is a life-threatening, developmental disease characterized by mental retardation, cataracts and renal failure. Although this human illness has been linked to defective function of the phosphatidylinositol 5-phosphatase, Ocrl1 (<unl>O</unl>culo-<unl>C</unl>erebro-<unl>R</unl>enal syndrome of <unl>L</unl>owe protein <unl>1</unl>), the mechanism by which this enzyme deficiency triggers the disease is not clear. Ocrl1 is known to localize mainly to the Golgi apparatus and endosomes, however it translocates to plasma membrane ruffles upon cell stimulation with growth factors. The functional implications of this inducible translocation to the plasma membrane are presently unknown. Here we show that Ocrl1 is required for proper cell migration, spreading and fluid-phase uptake in both established cell lines and human dermal fibroblasts. We found that primary fibroblasts from two patients diagnosed with LS displayed defects in these cellular processes. Importantly, these abnormalities were suppressed by expressing wild-type Ocrl1 but not by a phosphatase-deficient mutant. Interestingly, the homologous human PI-5-phosphatase, Inpp5b, was unable to complement the Ocrl1-dependent cell migration defect. Further, Ocrl1 variants that cannot bind the endocytic adaptor AP2 or clathrin, like Inpp5b, were less apt to rescue the migration phenotype. However, no defect in membrane recruitment of AP2/clathrin or in transferrin endocytosis by patient cells was detected. Collectively, our results suggest that Ocrl1, but not Inpp5b, is involved in ruffle-mediated membrane remodeling. Our results provide new elements for understanding how Ocrl1 deficiency leads to the abnormalities associated with the LS.</p>
]]></description>
<dc:creator><![CDATA[Coon, B. G., Mukherjee, D., Hanna, C. B., Riese, D. J., Lowe, M., Aguilar, R. C.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:11 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp407</dc:identifier>
<dc:title><![CDATA[Lowe syndrome patient fibroblasts display Ocrl1-specific cell migration defects that cannot be rescued by the homologous Inpp5b phosphatase]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4491</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4478</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4492?rss=1">
<title><![CDATA[X11{beta} rescues memory and long-term potentiation deficits in Alzheimer's disease APPswe Tg2576 mice]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4492?rss=1</link>
<description><![CDATA[
<p>Increased production and deposition of amyloid &beta;-protein (A&beta;) are believed to be key pathogenic events in Alzheimer's disease. As such, routes for lowering cerebral A&beta; levels represent potential therapeutic targets for Alzheimer's disease. X11&beta; is a neuronal adaptor protein that binds to the intracellular domain of the amyloid precursor protein (APP). Overexpression of X11&beta; inhibits A&beta; production in a number of experimental systems. However, whether these changes to APP processing and A&beta; production induced by X11&beta; overexpression also induce beneficial effects to memory and synaptic plasticity are not known. We report here that X11&beta;-mediated reduction in cerebral A&beta; is associated with normalization of both cognition and <I>in vivo</I> long-term potentiation in aged APPswe Tg2576 transgenic mice that model the amyloid pathology of Alzheimer's disease. Overexpression of X11&beta; itself has no detectable adverse effects upon mouse behaviour. These findings support the notion that modulation of X11&beta; function represents a therapeutic target for A&beta;-mediated neuronal dysfunction in Alzheimer's disease.</p>
]]></description>
<dc:creator><![CDATA[Mitchell, J. C., Ariff, B. B., Yates, D. M., Lau, K.-F., Perkinton, M. S., Rogelj, B., Stephenson, J. D., Miller, C. C.J., McLoughlin, D. M.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:11 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp408</dc:identifier>
<dc:title><![CDATA[X11{beta} rescues memory and long-term potentiation deficits in Alzheimer's disease APPswe Tg2576 mice]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4500</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4492</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4501?rss=1">
<title><![CDATA[Common fragile sites are characterized by histone hypoacetylation]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4501?rss=1</link>
<description><![CDATA[
<p>Common fragile sites (CFSs) represent large, highly unstable regions of the human genome. CFS sequences are sensitive to perturbation of replication; however, the molecular basis for the instability at CFSs is poorly understood. We hypothesized that a unique epigenetic pattern may underlie the unusual sensitivity of CFSs to replication interference. To examine this hypothesis, we analyzed chromatin modification patterns within the six human CFSs with the highest levels of breakage, and their surrounding non-fragile regions (NCFSs). Chromatin at most of the CFSs analyzed has significantly less histone acetylation than that of their surrounding NCFSs. Trichostatin A and/or 5-azadeoxycytidine treatment reduced chromosome breakage at CFSs. Furthermore, chromatin at the most commonly expressed CFS, the FRA3B, is more resistant to micrococcal nuclease than that of the flanking non-fragile sequences. These results demonstrate that histone hypoacetylation is a characteristic epigenetic pattern of CFSs, and chromatin within CFSs might be relatively more compact than that of the NCFSs, indicating a role for chromatin conformation in genomic instability at CFSs. Moreover, lack of histone acetylation at CFSs may contribute to the defective response to replication stress characteristic of CFSs, leading to the genetic instability characteristic of this regions.</p>
]]></description>
<dc:creator><![CDATA[Jiang, Y., Lucas, I., Young, D. J., Davis, E. M., Karrison, T., Rest, J. S., Le Beau, M. M.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp410</dc:identifier>
<dc:title><![CDATA[Common fragile sites are characterized by histone hypoacetylation]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4512</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4501</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4513?rss=1">
<title><![CDATA[An allergy-associated polymorphism in a novel regulatory element enhances IL13 expression]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4513?rss=1</link>
<description><![CDATA[
<p>IL-13 is a central effector of Th2-mediated allergic inflammation and is critical for the induction of IgE synthesis. Common <I>IL13</I> variants are associated with allergy phenotypes in populations of distinct ethnic background. We recently demonstrated that <I>IL13</I> expression by human CD4<sup>+</sup> T cells is paralleled by extensive <I>IL13</I> locus remodeling, which results in the appearance of multiple DNase I hypersensitive sites. Among these, HS4 in the distal promoter is constitutive in both na&iuml;ve and polarized Th1 and Th2 cells, and spans a common single nucleotide polymorphism, <I>IL13</I>-1512A&gt;C (rs1881457), strongly associated with total serum IgE levels. We recently characterized HS4 as a novel <I>cis</I>-acting element that upregulates <I>IL13</I> transcription in activated human and murine T cells. Here we show that <I>IL13</I>-1512A&gt;C is a functional polymorphism that significantly enhances HS4-dependent <I>IL13</I> expression by creating a binding site for the transcription factor Oct-1. Of note, endogenous Oct-1 was preferentially recruited to the <I>IL13</I>-1512C risk allele in primary CD4<sup>+</sup> T cells from <I>IL13</I>-1512A&gt;C heterozygous subjects. Moreover, the <I>IL13</I>-1512C allele was overexpressed in transfected Th2 cells from <I>Oct1</I><sup>+/+</sup> mice, but not from <I>Oct1</I><sup>+/&ndash;</sup> mice, demonstrating that increased activity was exquisitely dependent on physiologic levels of Oct-1. Our results illustrate how a functional variant in a regulatory element enhances transcription of an allergy-associated gene, thereby modulating disease susceptibility.</p>
]]></description>
<dc:creator><![CDATA[Kiesler, P., Shakya, A., Tantin, D., Vercelli, D.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp411</dc:identifier>
<dc:title><![CDATA[An allergy-associated polymorphism in a novel regulatory element enhances IL13 expression]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4520</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4513</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4521?rss=1">
<title><![CDATA[Functional analysis of 5-lipoxygenase promoter repeat variants]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4521?rss=1</link>
<description><![CDATA[
<p>Variants of a hexanucleotide repeat polymorphism in the promoter of the 5-lipoxygenase (<I><I>5-LO</I></I>) gene have been associated with cardiovascular disease traits in humans, which may be due, at least in part, to differential expression of the at-risk alleles. To more fully characterize these variants, we carried out gene expression and DNA methylation studies in primary leukocytes from healthy individuals carrying various <I><I>5-LO</I></I> promoter alleles. Regardless of genotype, <I><I>5-LO</I></I> and <I>5-LO</I>-activating protein (<I>FLAP</I>) gene expression was higher in granulocytes compared with monocytes and lymphocytes, whereas leukotriene A<SUB>4</SUB> hydrolase (<I>LTA4H</I>) expression was higher in monocytes. In all three leukocyte populations, <I>5-LO</I> mRNA levels were positively correlated with those of <I>FLAP</I> and <I>LTA4H</I>, with the highest correlation observed in granulocytes. In lymphocytes, individuals homozygous for the shorter 3 and 4 repeat alleles had between 20&ndash;35% higher <I>5-LO</I>, <I>FLAP</I> and <I>LTA4H</I> expression compared with homozygous carriers of the wild-type 5 repeat allele (<I>P</I> = 0.03&ndash;0.0001). DNA methylation analysis of four CpG islands in a 1500 bp region encompassing the <I>5-LO</I> promoter and the first ~100 bp of intron 1 revealed relatively low overall DNA methylation across all genotypes and leukocyte populations. However, analysis of the promoter repeats themselves demonstrated that, regardless of cell population, the 4 allele was methylated approximately twice as much as the 3 allele (<I>P</I> &lt; 0.0001). Our results demonstrate that, in lymphocytes, the shorter repeat alleles of the <I>5-LO</I> promoter lead to higher gene expression, which may be regulated through differential DNA methylation of the CpGs located within these repeats.</p>
]]></description>
<dc:creator><![CDATA[Vikman, S., Brena, R. M., Armstrong, P., Hartiala, J., Stephensen, C. B., Allayee, H.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp414</dc:identifier>
<dc:title><![CDATA[Functional analysis of 5-lipoxygenase promoter repeat variants]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4529</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4521</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4530?rss=1">
<title><![CDATA[The ocular albinism type 1 (OA1) G-protein-coupled receptor functions with MART-1 at early stages of melanogenesis to control melanosome identity and composition]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4530?rss=1</link>
<description><![CDATA[
<p>OA1 (GPR143; GPCR, G-protein-coupled receptor), the protein product of the ocular albinism type 1 gene, encodes a pigment-cell-specific GPCR that localizes intracellularly to melanosomes. OA1 mutations result in ocular albinism due to alterations in melanosome formation, suggesting that OA1 is a key player in the biogenesis of melanosomes. To address the function of OA1 in melanosome biogenesis, we have used siRNA inactivation and combined morphological and biochemical methods to investigate melanosome ultrastructure, melanosomal protein localization and expression in human pigmented melanocytic cells. OA1 loss of function leads to decreased pigmentation and causes formation of enlarged aberrant premelanosomes harboring disorganized fibrillar structures and displaying proteins of mature melanosomes and lysosomes at their membrane. Moreover, we show that OA1 interacts biochemically with the premelanosomal protein MART-1. Inactivation of MART-1 by siRNA leads to a decreased stability of OA1 and is accompanied by similar defects in premelanosome biogenesis and composition. These data show for the first time that melanosome composition and identity are regulated at early stages by OA1 and that MART-1 likely acts as an escort protein for this GPCR.</p>
]]></description>
<dc:creator><![CDATA[Giordano, F., Bonetti, C., Surace, E. M., Marigo, V., Raposo, G.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp415</dc:identifier>
<dc:title><![CDATA[The ocular albinism type 1 (OA1) G-protein-coupled receptor functions with MART-1 at early stages of melanogenesis to control melanosome identity and composition]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4545</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4530</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4546?rss=1">
<title><![CDATA[Pathogenic NAP57 mutations decrease ribonucleoprotein assembly in dyskeratosis congenita]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4546?rss=1</link>
<description><![CDATA[
<p>X-linked dyskeratosis congenita (DC) is a rare bone marrow failure syndrome caused by mostly missense mutations in the pseudouridine synthase NAP57 (dyskerin/Cbf5). As part of H/ACA ribonucleoproteins (RNPs), NAP57 is important for the biogenesis of ribosomes, spliceosomal small nuclear RNPs, microRNAs and the telomerase RNP. DC mutations concentrate in the N- and C-termini of NAP57 but not in its central catalytic domain raising questions as to their impact. We demonstrate that the N- and C-termini together form the binding surface for the H/ACA RNP assembly factor SHQ1 and that DC mutations modulate the interaction between the two proteins. Pinpointing impaired interaction between NAP57 and SHQ1 as a potential molecular basis for X-linked DC has implications for therapeutic approaches, e.g. by targeting the NAP57&ndash;SHQ1 interface with small molecules.</p>
]]></description>
<dc:creator><![CDATA[Grozdanov, P. N., Fernandez-Fuentes, N., Fiser, A., Meier, U. T.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp416</dc:identifier>
<dc:title><![CDATA[Pathogenic NAP57 mutations decrease ribonucleoprotein assembly in dyskeratosis congenita]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4551</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4546</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4552?rss=1">
<title><![CDATA[Mutant SOD1 in neuronal mitochondria causes toxicity and mitochondrial dynamics abnormalities]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4552?rss=1</link>
<description><![CDATA[
<p>Amyotrophic lateral sclerosis (ALS) is a fatal neurological disorder characterized by motor neuron degeneration. Mutations in Cu,Zn-superoxide dismutase (SOD1) are responsible for 20% of familial ALS cases via a toxic gain of function. In mutant SOD1 transgenic mice, mitochondria of spinal motor neurons develop abnormal morphology, bioenergetic defects and degeneration, which are presumably implicated in disease pathogenesis. SOD1 is mostly a cytosolic protein, but a substantial portion is associated with organelles, including mitochondria, where it localizes predominantly in the intermembrane space (IMS). However, whether mitochondrial mutant SOD1 contributes to disease pathogenesis remains to be elucidated. We have generated NSC34 motor neuronal cell lines expressing wild-type or mutant SOD1 containing a cleavable IMS targeting signal to directly investigate the pathogenic role of mutant SOD1 in mitochondria. We show that mitochondrially-targeted SOD1 localizes to the IMS, where it is enzymatically active. We prove that mutant IMS-targeted SOD1 causes neuronal toxicity under metabolic and oxidative stress conditions. Furthermore, we demonstrate for the first time neurite mitochondrial fragmentation and impaired mitochondrial dynamics in motor neurons expressing IMS mutant SOD1. These defects are associated with impaired maintenance of neuritic processes. Our findings demonstrate that mutant SOD1 localized in the IMS is sufficient to determine mitochondrial abnormalities and neuronal toxicity, and contributes to ALS pathogenesis.</p>
]]></description>
<dc:creator><![CDATA[Magrane, J., Hervias, I., Henning, M. S., Damiano, M., Kawamata, H., Manfredi, G.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp421</dc:identifier>
<dc:title><![CDATA[Mutant SOD1 in neuronal mitochondria causes toxicity and mitochondrial dynamics abnormalities]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4564</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4552</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4565?rss=1">
<title><![CDATA[A mouse model for Meckel syndrome reveals Mks1 is required for ciliogenesis and Hedgehog signaling]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4565?rss=1</link>
<description><![CDATA[
<p>Meckel syndrome (MKS) is a rare autosomal recessive disease causing perinatal lethality associated with a complex syndrome that includes occipital meningoencephalocele, hepatic biliary ductal plate malformation, postaxial polydactyly and polycystic kidneys. The gene mutated in type 1 MKS encodes a protein associated with the base of the cilium in vertebrates and nematodes. However, shRNA knockdown studies in cell culture have reported conflicting results on the role of Mks1 in ciliogenesis. Here we show that loss of function of mouse <I>Mks1</I> results in an accurate model of human MKS, with structural abnormalities in the neural tube, biliary duct, limb patterning, bone development and the kidney that mirror the human syndrome. In contrast to cell culture studies, loss of <I>Mks1 in vivo</I> does not interfere with apical localization of epithelial basal bodies but rather leads to defective cilia formation in most, but not all, tissues. Analysis of patterning in the neural tube and the limb demonstrates altered Hedgehog (Hh) pathway signaling underlies some MKS defects, although both tissues show an expansion of the domain of response to Shh signaling, unlike the phenotypes seen in other mutants with cilia loss. Other defects in the skull, lung, rib cage and long bones are likely to be the result of the disruption of Hh signaling, and the basis of defects in the liver and kidney require further analysis. Thus the disruption of Hh signaling can explain many, but not all, of the defects caused by loss of Mks1.</p>
]]></description>
<dc:creator><![CDATA[Weatherbee, S. D., Niswander, L. A., Anderson, K. V.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp422</dc:identifier>
<dc:title><![CDATA[A mouse model for Meckel syndrome reveals Mks1 is required for ciliogenesis and Hedgehog signaling]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4575</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4565</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4576?rss=1">
<title><![CDATA[Interaction between environmental and genetic factors modulates schizophrenic endophenotypes in the Snap-25 mouse mutant blind-drunk]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4576?rss=1</link>
<description><![CDATA[
<p>To understand the pathophysiology of neuropsychiatric disorders such as schizophrenia requires consideration of multiple genetic and non-genetic factors. However, very little is known about the consequences of combining models of synaptic dysfunction with controlled environmental manipulations. Therefore, to generate new insights into gene&ndash;environment interactions and complex behaviour, we examined the influence of variable prenatal stress (PNS) on two mouse lines with mutations in synaptosomal-associated protein of 25 kDa (Snap-25): the <I>blind-drunk</I> (<I>Bdr</I>) point mutant and heterozygous <I>Snap-25</I> knockout mice. Neonatal development was analysed in addition to an assessment of adult behavioural phenotypes relevant to the psychotic, cognitive and negative aspects of schizophrenia. These data show that PNS influenced specific anxiety-related behaviour in all animals. In addition, sensorimotor gating deficits previously noted in <I>Bdr</I> mutants were markedly enhanced by PNS; significantly, these effects could be reversed with the application of anti-psychotic drugs. Moreover, social interaction abnormalities were observed only in <I>Bdr</I> animals from stressed dams but not in wild-type littermates or mutants from non-stressed mothers. These results show for the first time that combining a synaptic mouse point mutant with a controlled prenatal stressor paradigm produces both modified and previously unseen phenotypes, generating new insights into the interactions between genetics and the environment relevant to the study of psychiatric disease.</p>
]]></description>
<dc:creator><![CDATA[Oliver, P. L., Davies, K. E.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp425</dc:identifier>
<dc:title><![CDATA[Interaction between environmental and genetic factors modulates schizophrenic endophenotypes in the Snap-25 mouse mutant blind-drunk]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4589</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4576</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4590?rss=1">
<title><![CDATA[CDKL5 influences RNA splicing activity by its association to the nuclear speckle molecular machinery]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4590?rss=1</link>
<description><![CDATA[
<p>Mutations in the human X-linked cyclin-dependent kinase-like 5 (<I>CDKL5</I>) gene have been shown to cause severe neurodevelopmental disorders including infantile spasms, encephalopathy, West-syndrome and an early-onset variant of Rett syndrome. CDKL5 is a serine/threonine kinase whose involvement in Rett syndrome can be inferred by its ability to directly bind and mediate phosphorylation of MeCP2. However, it remains to be elucidated how CDKL5 exerts its function. Here, we report that CDKL5 localizes to specific nuclear foci referred to as nuclear speckles in both cell lines and tissues. These sub-nuclear structures are traditionally considered as storage/modification sites of pre-mRNA splicing factors. Interestingly, we provide evidence that CDKL5 regulates the dynamic behaviour of nuclear speckles. Indeed, CDKL5 overexpression leads to nuclear speckle disassembly, and this event is strictly dependent on its kinase activity. Conversely, its down-regulation affects nuclear speckle morphology leading to abnormally large and uneven speckles. Similar results were obtained for primary adult fibroblasts isolated from <I>CDKL5</I>-mutated patients. Altogether, these findings indicate that CDKL5 controls nuclear speckle morphology probably by regulating the phosphorylation state of splicing regulatory proteins. Nuclear speckles are dynamic sites that can continuously supply splicing factors to active transcription sites, where splicing occurs. Notably, we proved that CDKL5 influences alternative splicing, at least as proved in heterologous minigene assays. In conclusion, we provide evidence that CDKL5 is involved indirectly in pre-mRNA processing, by controlling splicing factor dynamics. These findings identify a biological process whose disregulation might affect neuronal maturation and activity in <I>CDKL5</I>-related disorders.</p>
]]></description>
<dc:creator><![CDATA[Ricciardi, S., Kilstrup-Nielsen, C., Bienvenu, T., Jacquette, A., Landsberger, N., Broccoli, V.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp426</dc:identifier>
<dc:title><![CDATA[CDKL5 influences RNA splicing activity by its association to the nuclear speckle molecular machinery]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4602</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4590</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4603?rss=1">
<title><![CDATA[Missense mutations in the SH3TC2 protein causing Charcot-Marie-Tooth disease type 4C affect its localization in the plasma membrane and endocytic pathway]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4603?rss=1</link>
<description><![CDATA[
<p>Mutations in <I>SH3TC2</I> (<I>KIAA1985</I>) cause Charcot-Marie-Tooth disease (CMT) type 4C, a demyelinating inherited neuropathy characterized by early-onset and scoliosis. Here we demonstrate that the SH3TC2 protein is present in several components of the endocytic pathway including early endosomes, late endosomes and clathrin-coated vesicles close to the <I>trans</I>-Golgi network and in the plasma membrane. Myristoylation of SH3TC2 in glycine 2 is necessary but not sufficient for the proper location of the protein in the cell membranes. In addition to myristoylation, correct anchoring also needs the presence of SH3 and TPR domains. Mutations that cause a stop codon and produce premature truncations that remove most of the TPR domains are expressed as the wild-type protein. In contrast, missense mutations in or around the region of the first-TPR domain are absent from early endosomes, reduced in plasma membrane and late endosomes and are variably present in clathrin-coated vesicles. Our findings suggest that the endocytic and membrane trafficking pathway is involved in the pathogenesis of CMT4C disease. We postulate that missense mutations of <I>SH3TC2</I> could impair communication between the Schwann cell and the axon causing an abnormal myelin formation.</p>
]]></description>
<dc:creator><![CDATA[Lupo, V., Galindo, M. I., Martinez-Rubio, D., Sevilla, T., Vilchez, J. J., Palau, F., Espinos, C.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp427</dc:identifier>
<dc:title><![CDATA[Missense mutations in the SH3TC2 protein causing Charcot-Marie-Tooth disease type 4C affect its localization in the plasma membrane and endocytic pathway]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4614</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4603</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4615?rss=1">
<title><![CDATA[Myosin VI is required for the proper maturation and function of inner hair cell ribbon synapses]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4615?rss=1</link>
<description><![CDATA[
<p>The ribbon synapses of auditory inner hair cells (IHCs) undergo morphological and electrophysiological transitions during cochlear development. Here we report that myosin VI (Myo6), an actin-based motor protein involved in genetic forms of deafness, is necessary for some of these changes to occur. By using post-embedding immunogold electron microscopy, we showed that Myo6 is present at the IHC synaptic active zone. In Snell's waltzer mutant mice, which lack Myo6, IHC ionic currents and ribbon synapse maturation proceeded normally until at least post-natal day 6. In adult mutant mice, however, the IHCs displayed immature potassium currents and still fired action potentials, as normally only observed in immature IHCs. In addition, the number of ribbons per IHC was reduced by 30%, and 30% of the remaining ribbons were morphologically immature. Ca<sup>2+</sup>-dependent exocytosis probed by capacitance measurement was markedly reduced despite normal Ca<sup>2+</sup> currents and the large proportion of morphologically mature synapses, which suggests additional defects, such as loose Ca<sup>2+</sup>-exocytosis coupling or inefficient vesicular supply. Finally, we provide evidence that Myo6 and otoferlin, a putative Ca<sup>2+</sup> sensor of synaptic exocytosis also involved in a genetic form of deafness, interact at the IHC ribbon synapse, and we suggest that this interaction is involved in the recycling of synaptic vesicles. Our findings thus uncover essential roles for Myo6 at the IHC ribbon synapse, in addition to that proposed in membrane turnover and anchoring at the apical surface of the hair cells.</p>
]]></description>
<dc:creator><![CDATA[Roux, I., Hosie, S., Johnson, S. L., Bahloul, A., Cayet, N., Nouaille, S., Kros, C. J., Petit, C., Safieddine, S.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp429</dc:identifier>
<dc:title><![CDATA[Myosin VI is required for the proper maturation and function of inner hair cell ribbon synapses]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4628</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4615</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4629?rss=1">
<title><![CDATA[GIGYF2 gene disruption in mice results in neurodegeneration and altered insulin-like growth factor signaling]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4629?rss=1</link>
<description><![CDATA[
<p>Grb10-Interacting GYF Protein 2 (GIGYF2) was initially identified through its interaction with Grb10, an adapter protein that binds activated IGF-I and insulin receptors. The <I>GIGYF2</I> gene maps to human chromosome 2q37 within a region linked to familial Parkinson's disease (PARK11 locus), and association of <I>GIGYF2</I> mutations with Parkinson's disease has been described in some but not other recent publications. This study investigated the consequences of <I>Gigyf2</I> gene disruption in mice. <I>Gigyf2</I> null mice undergo apparently normal embryonic development, but fail to feed and die within the first 2 post-natal days. Heterozygous <I>Gigyf2</I><sup>+/&ndash;</sup> mice survive to adulthood with no evident metabolic or growth defects. At 12&ndash;15 months of age, the <I>Gigyf2</I><sup>+/&ndash;</sup> mice begin to exhibit motor dysfunction manifested as decreased balance time on a rotating horizontal rod. This is associated with histopathological evidence of neurodegeneration and rare intracytoplasmic Lewy body-like inclusions in spinal anterior horn motor neurons. There are -synuclein positive neuritic plaques in the brainstem and cerebellum, but no abnormalities in the substantia nigra. Primary cultured embryo fibroblasts from <I>Gigyf2</I> null mice exhibit decreased IGF-I-stimulated IGF-I receptor tyrosine phosphorylation and augmented ERK1/2 phosphorylation. These data provide further evidence for an important role of GIGYF2 in age-related neurodegeneration and IGF pathway signaling.</p>
]]></description>
<dc:creator><![CDATA[Giovannone, B., Tsiaras, W. G., de la Monte, S., Klysik, J., Lautier, C., Karashchuk, G., Goldwurm, S., Smith, R. J.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp430</dc:identifier>
<dc:title><![CDATA[GIGYF2 gene disruption in mice results in neurodegeneration and altered insulin-like growth factor signaling]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4639</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4629</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4640?rss=1">
<title><![CDATA[Pharmacological activation of PPAR{beta}/{delta} stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4640?rss=1</link>
<description><![CDATA[
<p>A therapeutic strategy to treat Duchenne muscular dystrophy (DMD) involves identifying compounds that can elevate utrophin A expression in muscle fibers of affected patients. The dystrophin homologue utrophin A can functionally substitute for dystrophin when its levels are enhanced in the <I>mdx</I> mouse model of DMD. Utrophin A expression in skeletal muscle is regulated by mechanisms that promote the slow myofiber program. Since activation of peroxisome proliferator-activated receptor (PPAR) &beta;/ promotes the slow oxidative phenotype in skeletal muscle, we initiated studies to determine whether pharmacological activation of PPAR&beta;/ provides functional benefits to the <I>mdx</I> mouse. GW501516, a PPAR&beta;/ agonist, was found to stimulate utrophin A mRNA levels in C2C12 muscle cells through an element in the utrophin A promoter. Expression of PPAR&beta;/ was greater in skeletal muscles of <I>mdx</I> versus wild-type mice. We treated 5&ndash;7-week-old <I>mdx</I> mice with GW501516 for 4 weeks. This treatment increased the percentage of muscle fibers expressing slower myosin heavy chain isoforms and stimulated utrophin A mRNA levels leading to its increased expression at the sarcolemma. Expression of 1-syntrophin and &beta;-dystroglycan was restored to the sarcolemma. Improvement of <I>mdx</I> sarcolemmal integrity was evidenced by decreased intracellular IgM staining and decreased <I>in vivo</I> Evans blue dye (EBD) uptake. GW501516 treatment also conferred protection against eccentric contraction (ECC)-induced damage of <I>mdx</I> skeletal muscles, as shown by a decreased contraction-induced force drop and reduction of dye uptake during ECC. These results demonstrate that pharmacological activation of PPAR&beta;/ might provide functional benefits to DMD patients through enhancement of utrophin A expression.</p>
]]></description>
<dc:creator><![CDATA[Miura, P., Chakkalakal, J. V., Boudreault, L., Belanger, G., Hebert, R. L., Renaud, J.-M., Jasmin, B. J.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp431</dc:identifier>
<dc:title><![CDATA[Pharmacological activation of PPAR{beta}/{delta} stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4649</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4640</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4650?rss=1">
<title><![CDATA[A genome-wide study of common SNPs and CNVs in cognitive performance in the CANTAB]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4650?rss=1</link>
<description><![CDATA[
<p>Psychiatric disorders such as schizophrenia are commonly accompanied by cognitive impairments that are treatment resistant and crucial to functional outcome. There has been great interest in studying cognitive measures as endophenotypes for psychiatric disorders, with the hope that their genetic basis will be clearer. To investigate this, we performed a genome-wide association study involving 11 cognitive phenotypes from the Cambridge Neuropsychological Test Automated Battery. We showed these measures to be heritable by comparing the correlation in 100 monozygotic and 100 dizygotic twin pairs. The full battery was tested in ~750 subjects, and for spatial and verbal recognition memory, we investigated a further 500 individuals to search for smaller genetic effects. We were unable to find any genome-wide significant associations with either SNPs or common copy number variants. Nor could we formally replicate any polymorphism that has been previously associated with cognition, although we found a weak signal of lower than expected <I>P</I>-values for variants in a set of 10 candidate genes. We additionally investigated SNPs in genomic loci that have been shown to harbor rare variants that associate with neuropsychiatric disorders, to see if they showed any suggestion of association when considered as a separate set. Only <I>NRXN1</I> showed evidence of significant association with cognition. These results suggest that common genetic variation does not strongly influence cognition in healthy subjects and that cognitive measures do not represent a more tractable genetic trait than clinical endpoints such as schizophrenia. We discuss a possible role for rare variation in cognitive genomics.</p>
]]></description>
<dc:creator><![CDATA[Need, A. C., Attix, D. K., McEvoy, J. M., Cirulli, E. T., Linney, K. L., Hunt, P., Ge, D., Heinzen, E. L., Maia, J. M., Shianna, K. V., Weale, M. E., Cherkas, L. F., Clement, G., Spector, T. D., Gibson, G., Goldstein, D. B.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp413</dc:identifier>
<dc:title><![CDATA[A genome-wide study of common SNPs and CNVs in cognitive performance in the CANTAB]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4661</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4650</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4662?rss=1">
<title><![CDATA[Genetic variation in GPR133 is associated with height: genome wide association study in the self-contained population of Sorbs]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4662?rss=1</link>
<description><![CDATA[
<p>Recently, associations of several common genetic variants with height have been reported in different populations. We attempted to identify further variants associated with adult height in a self-contained population (the Sorbs in Eastern Germany) as discovery set. We performed a genome wide association study (GWAS) (~390 000 genetic polymorphisms, Affymetrix gene arrays) on adult height in 929 Sorbian individuals. Subsequently, the best SNPs (<I>P</I> &lt; 0.001) were taken forward to a meta-analysis together with two independent cohorts [Diabetes Genetics Initiative, British 1958 Birth Cohort, (58BC, publicly available)]. Furthermore, we genotyped our best signal for replication in two additional German cohorts (Leipzig, <I>n</I> = 1044 and Berlin, <I>n</I> = 1728). In the primary Sorbian GWAS, we identified 5 loci with a <I>P</I>-value &lt; 10<sup>&ndash;5</sup> and 455 SNPs with <I>P</I>-value &lt; 0.001. In the meta-analysis on those 455 SNPs, only two variants in <I>GPR133</I> (rs1569019 and rs1976930; in LD with each other) retained a <I>P</I>-value at or below 10<sup>&ndash;6</sup> and were associated with height in the three cohorts individually. Upon replication, the SNP rs1569019 showed significant effects on height in the Leipzig cohort (<I>P</I> = 0.004, beta = 1.166) and in 577 men of the Berlin cohort (<I>P</I> = 0.049, beta = 1.127) though not in women. The combined analysis of all five cohorts (<I>n</I> = 6,687) resulted in a <I>P</I>-value of 4.7 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;8</sup> (beta = 0.949). In conclusion, our GWAS suggests novel loci influencing height. In view of the robust replication in five different cohorts, we propose <I>GPR133</I> to be a novel gene associated with adult height.</p>
]]></description>
<dc:creator><![CDATA[Tonjes, A., Koriath, M., Schleinitz, D., Dietrich, K., Bottcher, Y., Rayner, N. W., Almgren, P., Enigk, B., Richter, O., Rohm, S., Fischer-Rosinsky, A., Pfeiffer, A., Hoffmann, K., Krohn, K., Aust, G., Spranger, J., Groop, L., Bluher, M., Kovacs, P., Stumvoll, M.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp423</dc:identifier>
<dc:title><![CDATA[Genetic variation in GPR133 is associated with height: genome wide association study in the self-contained population of Sorbs]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4668</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4662</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4669?rss=1">
<title><![CDATA[Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4669?rss=1</link>
<description><![CDATA[
<p>Adiponutrin (<I>PNPLA3</I>) is a predominantly liver-expressed transmembrane protein with phospholipase activity that is regulated by fasting and feeding. Recent genome-wide association studies identified <I>PNPLA3</I> to be associated with hepatic fat content and liver function, thus pointing to a possible involvement in the hepatic lipoprotein metabolism. The aim of this study was to examine the association between two common variants in the adiponutrin gene and parameters of lipoprotein metabolism in 23 274 participants from eight independent West-Eurasian study populations including six population-based studies [Bruneck (<I>n</I> = 800), KORA S3/F3 (<I>n</I> = 1644), KORA S4/F4 (<I>n</I> = 1814), CoLaus (<I>n</I> = 5435), SHIP (<I>n</I> = 4012), Rotterdam (<I>n</I> = 5967)], the SAPHIR Study as a healthy working population (<I>n</I> = 1738) and the Utah Obesity Case-Control Study including a group of 1037 severely obese individuals (average BMI 46 kg/m<sup>2</sup>) and 827 controls from the same geographical region of Utah. We observed a strong additive association of a common non-synonymous variant within adiponutrin (rs738409) with age-, gender-, and alanine-aminotransferase-adjusted lipoprotein concentrations: each copy of the minor allele decreased levels of total cholesterol on average by 2.43 mg/dl (<I>P</I> = 8.87 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;7</sup>), non-HDL cholesterol levels by 2.35 mg/dl (<I>P</I> = 2.27 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;6</sup>) and LDL cholesterol levels by 1.48 mg/dl (<I>P</I> = 7.99 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;4</sup>). These associations remained significant after correction for multiple testing. We did not observe clear evidence for associations with HDL cholesterol or triglyceride concentrations. In conclusion, our study suggests that adiponutrin is involved in the metabolism of apoB-containing lipoproteins.</p>
]]></description>
<dc:creator><![CDATA[Kollerits, B., Coassin, S., Beckmann, N. D., Teumer, A., Kiechl, S., Doring, A., Kavousi, M., Hunt, S. C., Lamina, C., Paulweber, B., Kutalik, Z., Nauck, M., van Duijn, C. M., Heid, I. M., Willeit, J., Brandstatter, A., Adams, T. D., Mooser, V., Aulchenko, Y. S., Volzke, H., Kronenberg, F.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp424</dc:identifier>
<dc:title><![CDATA[Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4676</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4669</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4677?rss=1">
<title><![CDATA[Genome-wide significant predictors of metabolites in the one-carbon metabolism pathway]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4677?rss=1</link>
<description><![CDATA[
<p>Low plasma B-vitamin levels and elevated homocysteine have been associated with cancer, cardiovascular disease and neurodegenerative disorders. Common variants in <I>FUT2</I> on chromosome 19q13 were associated with plasma vitamin B<SUB>12</SUB> levels among women in a genome-wide association study in the Nurses&rsquo; Health Study (NHS) NCI-Cancer Genetic Markers of Susceptibility (CGEMS) project. To identify additional loci associated with plasma vitamin B<SUB>12</SUB>, homocysteine, folate and vitamin B<SUB>6</SUB> (active form pyridoxal 5'-phosphate, PLP), we conducted a meta-analysis of three GWA scans (total <I>n</I> = 4763, consisting of 1658 women in NHS-CGEMS, 1647 women in Framingham-SNP-Health Association Resource (SHARe) and 1458 men in SHARe). On chromosome 19q13, we confirm the association of plasma vitamin B<SUB>12</SUB> with rs602662 and rs492602 (<I>P</I>-value = 1.83 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;15</sup> and 1.30 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;14</sup>, respectively) in strong linkage disequilibrium (LD) with rs601338 (<I>P</I> = 6.92 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;15</sup>), the <I>FUT2 W143X</I> nonsense mutation. We identified additional genome-wide significant loci for plasma vitamin B<SUB>12</SUB> on chromosomes 6p21 (<I>P</I> = 4.05 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;08</sup>), 10p12 (<I>P</I>-value=2.87 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;9</sup>) and 11q11 (<I>P</I>-value=2.25 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;10</sup>) in genes with biological relevance. We confirm the association of the well-studied functional candidate SNP 5,10-<I>methylene tetrahydrofolate reductase (MTHFR) Ala222Val</I> (dbSNP ID: rs1801133; <I>P</I>-value=1.27 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;8</sup>), on chromosome 1p36 with plasma homocysteine and identify an additional genome-wide significant locus on chromosome 9q22 (<I>P</I>-value=2.06 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;8</sup>) associated with plasma homocysteine. We also identified genome-wide associations with variants on chromosome 1p36 with plasma PLP (<I>P</I>-value=1.40 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;15</sup>). Genome-wide significant loci were not identified for plasma folate. These data reveal new biological candidates and confirm prior candidate genes for plasma homocysteine, plasma vitamin B<SUB>12</SUB> and plasma PLP.</p>
]]></description>
<dc:creator><![CDATA[Hazra, A., Kraft, P., Lazarus, R., Chen, C., Chanock, S. J., Jacques, P., Selhub, J., Hunter, D. J.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp428</dc:identifier>
<dc:title><![CDATA[Genome-wide significant predictors of metabolites in the one-carbon metabolism pathway]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4687</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4677</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4688?rss=1">
<title><![CDATA[An increased frequency of the 5A allele in the promoter region of the MMP3 gene is associated with abdominal aortic aneurysms]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4688?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Deguara, J., Burnand, K. G., Berg, J., Green, P., Lewis, C. M., Chinien, G., Waltham, M., Taylor, P., Stern, R. F., Solomon, E., Smith, A.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp439</dc:identifier>
<dc:title><![CDATA[An increased frequency of the 5A allele in the promoter region of the MMP3 gene is associated with abdominal aortic aneurysms]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4688</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4688</prism:startingPage>
<prism:section>CORRIGENDUM</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/NP?rss=1">
<title><![CDATA[Contents Page]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/NP?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp448</dc:identifier>
<dc:title><![CDATA[Contents Page]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/NP-a?rss=1">
<title><![CDATA[Cover Page]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/NP-a?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp450</dc:identifier>
<dc:title><![CDATA[Cover Page]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/NP-b?rss=1">
<title><![CDATA[Editorial Board]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/NP-b?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp452</dc:identifier>
<dc:title><![CDATA[Editorial Board]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/NP-c?rss=1">
<title><![CDATA[Subscription Page]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/NP-c?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp454</dc:identifier>
<dc:title><![CDATA[Subscription Page]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4227?rss=1">
<title><![CDATA[Imprinting regulates mammalian snoRNA-encoding chromatin decondensation and neuronal nucleolar size]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4227?rss=1</link>
<description><![CDATA[
<p>Imprinting, non-coding RNA and chromatin organization are modes of epigenetic regulation that modulate gene expression and are necessary for mammalian neurodevelopment. The only two known mammalian clusters of genes encoding small nucleolar RNAs (snoRNAs), <I>SNRPN</I> through <I>UBE3A</I>(15q11&ndash;q13/7qC) and <I>GTL2</I>(14q32.2/12qF1), are neuronally expressed, localized to imprinted loci and involved in at least five neurodevelopmental disorders. Deficiency of the paternal 15q11&ndash;q13 snoRNA HBII-85 locus is necessary to cause the neurodevelopmental disorder Prader&ndash;Willi syndrome (PWS). Here we show epigenetically regulated chromatin decondensation at snoRNA clusters in human and mouse brain. An 8-fold allele-specific decondensation of snoRNA chromatin was developmentally regulated specifically in maturing neurons, correlating with HBII-85 nucleolar accumulation and increased nucleolar size. Reciprocal mouse models revealed a genetic and epigenetic requirement of the 35 kb imprinting center (IC) at the <I>Snrpn&ndash;Ube3a</I> locus for transcriptionally regulated chromatin decondensation. PWS human brain and IC deletion mouse Purkinje neurons showed significantly decreased nucleolar size, demonstrating the essential role of the 15q11&ndash;q13 HBII-85 locus in neuronal nucleolar maturation. These results are relevant to understanding the molecular pathogenesis of multiple human neurodevelopmental disorders, including PWS and some causes of autism.</p>
]]></description>
<dc:creator><![CDATA[Leung, K. N., Vallero, R. O., DuBose, A. J., Resnick, J. L., LaSalle, J. M.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp373</dc:identifier>
<dc:title><![CDATA[Imprinting regulates mammalian snoRNA-encoding chromatin decondensation and neuronal nucleolar size]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4238</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4227</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4239?rss=1">
<title><![CDATA[Knock-down of PQBP1 impairs anxiety-related cognition in mouse]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4239?rss=1</link>
<description><![CDATA[
<p>PQBP1 (polyglutamine tract-binding protein 1) is a causative gene for a relatively frequent X-linked syndromic and non-syndromic mental retardation (MR). To analyze behavioral abnormalities of these patients from molecular basis, we developed a knock-down (KD) mouse model. The KD mice possess a transgene expressing 498 bp double-strand RNA that is endogenously cleaved to siRNA suppressing PQBP1 efficiently. After confirming that PQBP1 is selectively suppressed to nearly 50% of the control mice, we performed behavioral analyses of PQBP1-KD mice. The KD mice possessed normal ability in ordinary memory tests including water-maze test, whereas they showed abnormal anxiety-related behavior in light/dark exploration test and open-field test and showed obvious declines of anxiety-related cognition in the repetitive elevated plus maze or novel object recognition test. Correspondingly, we found c-fos upregulation and histone H3 acetylation after behavior tests were declined in neurons of amygdala, prefrontal cortex and hippocampus. Furthermore, we found that 4-phenylbutyric acid, an HDAC inhibitor, efficiently improved expression of these genes and rescued the abnormal phenotypes in adult PQBP1-KD mice. These results suggested that PQBP1 dysfunction in regulating gene expression might underlie the abnormal behavior and cognition of PQBP1-KD mice and that the recovery of expression of such PQBP1 target genes might improve the symptoms in adult patients.</p>
]]></description>
<dc:creator><![CDATA[Ito, H., Yoshimura, N., Kurosawa, M., Ishii, S., Nukina, N., Okazawa, H.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp378</dc:identifier>
<dc:title><![CDATA[Knock-down of PQBP1 impairs anxiety-related cognition in mouse]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4254</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4239</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4255?rss=1">
<title><![CDATA[The interval between Ins2 and Ascl2 is dispensable for imprinting centre function in the murine Beckwith-Wiedemann region]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4255?rss=1</link>
<description><![CDATA[
<p>Imprinted genes are commonly clustered in domains across the mammalian genome, suggesting a degree of coregulation via long-range coordination of their monoallelic transcription. The distal end of mouse chromosome 7 (Chr 7) contains two clusters of imprinted genes within a ~1 Mb domain. This region is conserved on human 11p15.5 where it is implicated in the Beckwith&ndash;Wiedemann syndrome. In both species, imprinted regulation requires two critical <I>cis-</I>acting imprinting centres, carrying different germline epigenetic marks and mediating imprinted expression in the proximal and distal sub-domains. The clusters are separated by a region containing the gene for tyrosine hydroxylase (<I>Th</I>) as well as a high density of short repeats and retrotransposons in the mouse. We have used the Cre-<I>lox</I>P recombination system <I>in vivo</I> to engineer an interstitial deletion of this ~280-kb intervening region previously proposed to participate in the imprinting mechanism or to act as a boundary between the two sub-domains. The deletion allele, <I>Del</I><sup><I>7AI</I></sup>, is silent with respect to epigenetic marking at the two flanking imprinting centres. Reciprocal inheritance of <I>Del</I><sup><I>7AI</I></sup> demonstrates that the deleted region, which represents more than a quarter of the previously defined imprinted domain, is associated with intrauterine growth restriction in maternal heterozygotes. In homozygotes, the deficiency behaves as a <I>Th</I> null allele and can be rescued pharmacologically by bypassing the metabolic requirement for TH <I>in utero</I>. Our results show that the deleted interval is not required for normal imprinting on distal Chr 7 and uncover a new imprinted growth phenotype.</p>
]]></description>
<dc:creator><![CDATA[Lefebvre, L., Mar, L., Bogutz, A., Oh-McGinnis, R., Mandegar, M. A., Paderova, J., Gertsenstein, M., Squire, J. A., Nagy, A.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp379</dc:identifier>
<dc:title><![CDATA[The interval between Ins2 and Ascl2 is dispensable for imprinting centre function in the murine Beckwith-Wiedemann region]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4267</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4255</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4268?rss=1">
<title><![CDATA[Gp78, an ER associated E3, promotes SOD1 and ataxin-3 degradation]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4268?rss=1</link>
<description><![CDATA[
<p>Superoxide dismutase-1 (SOD1) and ataxin-3 are two neurodegenerative disease proteins in association with familial amyotrophic lateral sclerosis and Machado&ndash;Joseph disease/spinocerebellar ataxia type 3. Both normal and mutant types of SOD1 and ataxin-3 are degraded by the proteasome. It was recently reported that these two proteins are associated with the endoplasmic reticulum (ER). Mammalian gp78 is an E3 ubiquitin ligase involved in ER-associated degradation (ERAD). Here, we show that gp78 interacts with both SOD1 and ataxin-3. Overexpression of gp78 promotes the ubiquitination and degradation of these two proteins, whereas knockdown of gp78 stabilizes them. Moreover, gp78 represses aggregate formation of mutant SOD1 and protect cells against mutant SOD1-induced cell death. Furthermore, gp78 is increased in cells transfected with these two mutant proteins as well as in ALS mice. Thus, our results suggest that gp78 functions in the regulation of SOD1 and ataxin-3 to target them for ERAD.</p>
]]></description>
<dc:creator><![CDATA[Ying, Z., Wang, H., Fan, H., Zhu, X., Zhou, J., Fei, E., Wang, G.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp380</dc:identifier>
<dc:title><![CDATA[Gp78, an ER associated E3, promotes SOD1 and ataxin-3 degradation]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4281</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4268</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4282?rss=1">
<title><![CDATA[Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4282?rss=1</link>
<description><![CDATA[
<p>Spinocerebellar ataxia type 3 (SCA3) is caused by the expansion of a CAG repeat tract that affects the <I>MJD1</I> gene which encodes the ataxin-3 protein. In order to analyze whether symptoms caused by ataxin-3 with an expanded repeat are reversible <I>in vivo</I>, we generated a conditional mouse model of SCA3 using the Tet-Off system. We used a full-length human <I>ataxin-3</I> cDNA with 77 repeats in order to generate the responder mouse line. After crossbreeding with a <I>PrP</I> promoter mouse line, double transgenic mice developed a progressive neurological phenotype characterized by neuronal dysfunction in the cerebellum, reduced anxiety, hyperactivity, impaired Rotarod performance and lower body weight gain. When ataxin-3 expression was turned off in symptomatic mice in an early disease state, the transgenic mice were indistinguishable from negative controls after 5 months of treatment. These results show that reducing the production of pathogenic ataxin-3 indeed may be a promising approach to treat SCA3, provided that such treatment is applied before irreversible damage has taken place and that it is continued for a sufficiently long time.</p>
]]></description>
<dc:creator><![CDATA[Boy, J., Schmidt, T., Wolburg, H., Mack, A., Nuber, S., Bottcher, M., Schmitt, I., Holzmann, C., Zimmermann, F., Servadio, A., Riess, O.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp381</dc:identifier>
<dc:title><![CDATA[Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4295</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4282</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4296?rss=1">
<title><![CDATA[Expression quantitative trait loci detected in cell lines are often present in primary tissues]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4296?rss=1</link>
<description><![CDATA[
<p>Expression quantitative trait loci (eQTL) mapping is a powerful tool for identifying genetic regulatory variation. However, at present, most eQTLs in humans were identified using gene expression data from cell lines, and it remains unknown whether these eQTLs also have a regulatory function in other expression contexts, such as human primary tissues. Here we investigate this question using a targeted strategy. Specifically, we selected a subset of large-effect eQTLs identified in the HapMap lymphoblastoid cell lines, and examined the association of these eQTLs with gene expression levels across individuals in five human primary tissues (heart, kidney, liver, lung and testes). We show that genotypes at the eQTLs we selected are often predictive of variation in gene expression levels in one or more of the five primary tissues. The genotype effects in the primary tissues are consistently in the same direction as the effects inferred in the cell lines. Additionally, a number of the eQTLs we tested are found in more than one of the tissues. Our results indicate that functional studies in cell lines may uncover a substantial amount of genetic variation that affects gene expression levels in human primary tissues.</p>
]]></description>
<dc:creator><![CDATA[Bullaughey, K., Chavarria, C. I., Coop, G., Gilad, Y.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp382</dc:identifier>
<dc:title><![CDATA[Expression quantitative trait loci detected in cell lines are often present in primary tissues]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4303</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4296</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4304?rss=1">
<title><![CDATA[Stra13 regulates oxidative stress mediated skeletal muscle degeneration]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4304?rss=1</link>
<description><![CDATA[
<p>Duchenne Muscular Dystrophy (DMD), caused by loss of dystrophin is characterized by progressive muscle cell necrosis. However, the mechanisms leading to muscle degeneration in DMD are poorly understood. Here, we demonstrate that Stra13 protects muscle cells from oxidative damage, and its absence leads to muscle necrosis in response to injury in <I>Stra13-</I>deficient mice. Interestingly, <I>Stra13&ndash;/&ndash;</I> mutants express elevated levels of TNF, reduced levels of heme-oxygenase-1, and display apparent signs of oxidative stress prior to muscle death. Moreover, <I>Stra13&ndash;/&ndash;</I> muscle cells exhibit an increased sensitivity to pro-oxidants, and conversely, Stra13 overexpression provides resistance to oxidative damage. Consistently, treatment with anti-oxidant N-acetylcysteine ameliorates muscle necrosis in <I>Stra13&ndash;/&ndash;</I> mice. We also demonstrate that Stra13 expression is elevated in muscles from dystrophin-deficient (<I>mdx</I>) mice, and <I>mdx</I>/<I>Stra13&ndash;/&ndash;</I> double mutants exhibit an early onset of muscle degeneration. Our studies underscore the importance of oxidative stress-mediated muscle degeneration in muscular dystrophy, and reveal the contribution of Stra13 in maintenance of muscle integrity.</p>
]]></description>
<dc:creator><![CDATA[Vercherat, C., Chung, T.-K., Yalcin, S., Gulbagci, N., Gopinadhan, S., Ghaffari, S., Taneja, R.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp383</dc:identifier>
<dc:title><![CDATA[Stra13 regulates oxidative stress mediated skeletal muscle degeneration]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4316</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4304</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4317?rss=1">
<title><![CDATA[Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4317?rss=1</link>
<description><![CDATA[
<p>Autosomal-recessive mutations in the Parkin gene are the second most common cause of familial Parkinson's disease (PD). Parkin deficiency leads to the premature demise of the catecholaminergic neurons of the ventral midbrain in familial PD. Thus, a better understanding of parkin function may elucidate molecular aspects of their selective vulnerability in idiopathic PD. Numerous lines of evidence suggest a mitochondrial function for parkin and a protective effect of ectopic parkin expression. Since mitochondria play a critical role in cell survival/cell death through regulated cytochrome c release and control of apoptosis, we sought direct evidence of parkin function in this pathway. Mitochondria were isolated from cells expressing either excess levels of human parkin or shRNA directed against endogenous parkin and then treated with peptides corresponding to the active Bcl-2 homology 3 (BH3) domains of pro-apoptotic proteins and the threshold for cytochrome c release was analyzed. Data obtained from both rodent and human neuroblastoma cell lines showed that the expression levels of parkin were inversely correlated with cytochrome c release. Parkin was found associated with isolated mitochondria, but its binding <I>per se</I> was not sufficient to inhibit cytochrome c release. In addition, pathogenic parkin mutants failed to influence cytochrome c release. Furthermore, PINK1 expression had no effect on cytochrome c release, suggesting a divergent function for this autosomal recessive PD-linked gene. In summary, these data demonstrate a specific autonomous effect of parkin on mitochondrial mechanisms governing cytochrome c release and apoptosis, which may be relevant to the selective vulnerability of certain neuronal populations in PD.</p>
]]></description>
<dc:creator><![CDATA[Berger, A. K., Cortese, G. P., Amodeo, K. D., Weihofen, A., Letai, A., LaVoie, M. J.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp384</dc:identifier>
<dc:title><![CDATA[Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4328</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4317</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4329?rss=1">
<title><![CDATA[RPGRIP1 is essential for normal rod photoreceptor outer segment elaboration and morphogenesis]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4329?rss=1</link>
<description><![CDATA[
<p>The function of the retinitis pigmentosa GTPase regulator interacting protein 1 (<I>RPGRIP1</I>) gene is currently not known. However, mutations within the gene lead to Leber Congenital Amaurosis and autosomal recessive retinitis pigmentosa in human patients. In a previously described knockout mouse model of the long splice variant of <I>Rpgrip1</I>, herein referred to as <I>Rpgrip1</I><sup><I>tm1Tili</I></sup> mice, mislocalization of key outer segment proteins and dysmorphogenesis of outer segment discs preceded subsequent photoreceptor degeneration. In this report, we describe a new mouse model carrying a splice acceptor site mutation in <I>Rpgrip1</I>, herein referred to as <I>Rpgrip1</I><sup><I>nmf247</I></sup> that is phenotypically distinct from <I>Rpgrip1</I><sup><I>tm1Tili</I></sup> mice. Photoreceptor degeneration in homozygous <I>Rpgrip1</I><sup><I>nmf247</I></sup> mice is earlier in onset and more severe when compared with <I>Rpgrip1</I><sup><I>tm1Tili</I></sup> mice. Also, ultrastructural studies reveal that whereas <I>Rpgrip1</I><sup><I>nmf247</I></sup> mutants have a normal structure and number of connecting cilia, unlike <I>Rpgrip1</I><sup><I>tm1Tili</I></sup> mice, they do not elaborate rod outer segments (OS). Therefore, in addition to its role in OS disc morphogenesis, RPGRIP1 is essential for rod OS formation. Our study indicates the absence of multiple <I>Rpgrip1</I> isoforms in <I>Rpgrip1</I><sup><I>nmf247</I></sup> mice, suggesting different isoforms may play different roles in photoreceptors and underscores the importance of considering splice variants when generating targeted null mutations.</p>
]]></description>
<dc:creator><![CDATA[Won, J., Gifford, E., Smith, R. S., Yi, H., Ferreira, P. A., Hicks, W. L., Li, T., Naggert, J. K., Nishina, P. M.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp385</dc:identifier>
<dc:title><![CDATA[RPGRIP1 is essential for normal rod photoreceptor outer segment elaboration and morphogenesis]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4339</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4329</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4340?rss=1">
<title><![CDATA[Pluripotency can be rapidly and efficiently induced in human amniotic fluid-derived cells]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4340?rss=1</link>
<description><![CDATA[
<p>Direct reprogramming of human somatic cells into pluripotency has broad implications in generating patient-specific induced pluripotent stem (iPS) cells for disease modeling and cellular replacement therapies. However, the low efficiency and safety issues associated with generation of human iPS cells have limited their usage in clinical settings. Cell types can significantly influence reprogramming efficiency and kinetics. To date, human iPS cells have been obtained only from a few cell types. Here, we report for the first time rapid and efficient generation of iPS cells from human amniotic fluid-derived cells (hAFDCs) via ectopic expression of four human factors: <I>OCT4</I>/<I>SOX2</I>/<I>KLF4</I>/<I>C-MYC</I>. Significantly, typical single iPS cell colonies can be picked up 6 days after viral infection with high efficiency. Eight iPS cell lines have been derived. They can be continuously propagated <I>in vitro</I> and express pluripotency markers such as AKP, OCT4, SOX2, SSEA4, TRA-1-60 and TRA-1-81, maintaining the normal karyotype. Transgenes are completely inactivated and the endogenous <I>OCT4</I> promoter is adequately demethylated in the established iPS cell lines. Moreover, various cells and tissues from all three germ layers are found in embryoid bodies and teratomas, respectively. In addition, microarray analysis demonstrates a high correlation coefficient between hAFDC-iPS cells and human embryonic stem cells, but a low correlation coefficient between hAFDCs and hAFDC-iPS cells. Taken together, these data identify an ideal human somatic cell resource for rapid and efficient generation of iPS cells, allowing us to establish human iPS cells using more advanced approaches and possibly to establish disease- or patient-specific iPS cells.</p>
]]></description>
<dc:creator><![CDATA[Li, C., Zhou, J., Shi, G., Ma, Y., Yang, Y., Gu, J., Yu, H., Jin, S., Wei, Z., Chen, F., Jin, Y.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp386</dc:identifier>
<dc:title><![CDATA[Pluripotency can be rapidly and efficiently induced in human amniotic fluid-derived cells]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4349</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4340</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4350?rss=1">
<title><![CDATA[Deficiency in COG5 causes a moderate form of congenital disorders of glycosylation]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4350?rss=1</link>
<description><![CDATA[
<p>The conserved oligomeric Golgi (COG) complex is a tethering factor composed of eight subunits that is involved in the retrograde transport of intra-Golgi components. Deficient biosynthesis of COG subunits leads to alterations of protein trafficking along the secretory pathway and thereby to severe diseases in humans. Since the COG complex affects the localization of several Golgi glycosyltransferase enzymes, COG deficiency also leads to defective protein glycosylation, thereby explaining the classification of COG deficiencies as forms of congenital disorders of glycosylation (CDG). To date, mutations in <I>COG1</I>, <I>COG4</I>, <I>COG7</I> and <I>COG8</I> genes have been associated with diseases, which range from severe multi-organ disorders to moderate forms of neurological impairment. In the present study, we describe a new type of COG deficiency related to a splicing mutation in the <I>COG5</I> gene. Sequence analysis in the patient identified a homozygous intronic substitution (c.1669-15T&gt;C) leading to exon skipping and severely reduced expression of the COG5 protein. This defect was associated with a mild psychomotor retardation with delayed motor and language development. Analysis of different serum glycoproteins revealed a CDG phenotype with typical undersialylation of N- and O-glycans. Retrograde Golgi-to-endoplasmic reticulum trafficking was markedly delayed in the patient's fibroblast upon brefeldin-A treatment, which is a hallmark of COG deficiency. This trafficking delay could be restored to normal values by expressing a wild-type COG5 cDNA in the patient cells. This case demonstrates that COG deficiency and thereby CDG must be taken into consideration even in children presenting mild neurological impairments.</p>
]]></description>
<dc:creator><![CDATA[Paesold-Burda, P., Maag, C., Troxler, H., Foulquier, F., Kleinert, P., Schnabel, S., Baumgartner, M., Hennet, T.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp389</dc:identifier>
<dc:title><![CDATA[Deficiency in COG5 causes a moderate form of congenital disorders of glycosylation]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4356</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4350</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4357?rss=1">
<title><![CDATA[ALX4 dysfunction disrupts craniofacial and epidermal development]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4357?rss=1</link>
<description><![CDATA[
<p>Genetic control of craniofacial morphogenesis requires a complex interaction of numerous genes encoding factors essential for patterning and differentiation. We present two Turkish families with a new autosomal recessive frontofacial dysostosis syndrome characterized by total alopecia, a large skull defect, coronal craniosynostosis, hypertelorism, severely depressed nasal bridge and ridge, bifid nasal tip, hypogonadism, callosal body agenesis and mental retardation. Using homozygosity mapping, we mapped the entity to chromosome 11p11.2&ndash;q12.3 and subsequently identified a homozygous c.793C-&gt;T nonsense mutation in the human ortholog of the mouse aristaless-like homeobox 4 (<I>ALX4</I>) gene. This mutation is predicted to result in a premature stop codon (p.R265X) of <I>ALX4</I> truncating 146 amino acids of the protein including a part of the highly conserved homeodomain and the C-terminal paired tail domain. Although the RNA is stable and not degraded by nonsense-mediated RNA decay, the mutant protein is likely to be non-functional. In a skin biopsy of an affected individual, we observed a hypomorphic interfollicular epidermis with reduced suprabasal layers associated with impaired interfollicular epidermal differentiation. Hair follicle-like structures were present but showed altered differentiation. Our data indicate that <I>ALX4</I> plays a critical role both in craniofacial development as in skin and hair follicle development in human.</p>
]]></description>
<dc:creator><![CDATA[Kayserili, H., Uz, E., Niessen, C., Vargel, I., Alanay, Y., Tuncbilek, G., Yigit, G., Uyguner, O., Candan, S., Okur, H., Kaygin, S., Balci, S., Mavili, E., Alikasifoglu, M., Haase, I., Wollnik, B., Akarsu, N. A.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp391</dc:identifier>
<dc:title><![CDATA[ALX4 dysfunction disrupts craniofacial and epidermal development]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4366</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4357</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4367?rss=1">
<title><![CDATA[Mice defective in Trpm6 show embryonic mortality and neural tube defects]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4367?rss=1</link>
<description><![CDATA[
<p>The syndrome of hypomagnesemia with secondary hypocalcemia is caused by defective TRPM6. This protein is an ion channel that also contains a kinase in its C-terminus. It is usually diagnosed in childhood and, without treatment with supplemental Mg, affected children suffer from mental retardation, seizures and retarded development. We developed a mouse lacking <I>Trpm6</I> in order to understand in greater detail the function of this protein. In contrast to our expectations, <I>Trpm6</I><sup>&ndash;/&ndash;</sup> mice almost never survived to weaning. Many mice died by embryonic day 12.5. Most that survived to term had neural tube defects consisting of both exencephaly and spina bifida occulta, an unusual combination. Feeding dams a high Mg diet marginally improved offspring survival to weaning. The few <I>Trpm6</I><sup>&ndash;/&ndash;</sup> mice that survived were fertile but matings between <I>Trpm6</I><sup>&ndash;/&ndash;</sup> mice produced no viable pregnancies. <I>Trpm6</I><sup>+/&ndash;</sup> mice had normal electrolytes except for modestly low plasma [Mg]. In addition, some <I>Trpm6</I><sup>+/&ndash;</sup> mice died prematurely. Absence of Trpm6 produces an apparently different phenotype in mice than in humans. The presence of neural tube defects identifies a previously unsuspected role of Trpm6 in effecting neural tube closure. This genetic defect produces one of very few mouse models of spina bifida occulta. These results point to a critical role of Trpm6 in development and suggest an important role in neural tube closure.</p>
]]></description>
<dc:creator><![CDATA[Walder, R. Y., Yang, B., Stokes, J. B., Kirby, P. A., Cao, X., Shi, P., Searby, C. C., Husted, R. F., Sheffield, V. C.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp392</dc:identifier>
<dc:title><![CDATA[Mice defective in Trpm6 show embryonic mortality and neural tube defects]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4375</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4367</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4376?rss=1">
<title><![CDATA[Transplantation directs oocyte maturation from embryonic stem cells and provides a therapeutic strategy for female infertility]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4376?rss=1</link>
<description><![CDATA[
<p>Ten to 15% of couples are infertile, with the most common causes being linked to the production of few or no oocytes or sperm. Yet, our understanding of human germ cell development is poor, at least in part due to the inaccessibility of early stages to genetic and developmental studies. Embryonic stem cells (ESCs) provide an <I>in vitro</I> system to study oocyte development and potentially treat female infertility. However, most studies of ESC differentiation to oocytes have not documented fundamental properties of endogenous development, making it difficult to determine the physiologic relevance of differentiated germ cells. Here, we sought to establish fundamental parameters of oocyte development during ESC differentiation to explore suitability for basic developmental genetic applications using the mouse as a model prior to translating to the human system. We demonstrate a timeline of definitive germ cell differentiation from ESCs <I>in vitro</I> that initially parallels endogenous oocyte development <I>in vivo</I> by single-cell expression profiling and analysis of functional milestones including responsiveness to defined maturation media, shared genetic requirement of <I>Dazl</I>, and entry into meiosis. However, ESC-derived oocyte maturation ultimately fails <I>in vitro</I>. To overcome this obstacle, we transplant ESC-derived oocytes into an ovarian niche to direct their functional maturation and, thereby, present rigorous evidence of oocyte physiologic relevance and a potential therapeutic strategy for infertility.</p>
]]></description>
<dc:creator><![CDATA[Nicholas, C. R., Haston, K. M., Grewall, A. K., Longacre, T. A., Reijo Pera, R. A.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp393</dc:identifier>
<dc:title><![CDATA[Transplantation directs oocyte maturation from embryonic stem cells and provides a therapeutic strategy for female infertility]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4389</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4376</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4390?rss=1">
<title><![CDATA[Leucine-rich repeat kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4390?rss=1</link>
<description><![CDATA[
<p>Mutations in the <I>LRRK2</I> gene are the most common genetic cause of familial Parkinson's disease (PD). However, its physiological and pathological functions are unknown. Therefore, we generated several independent <I>Drosophila</I> lines carrying WT or mutant human <I>LRRK2</I> (mutations in kinase, COR or LRR domains, resp.). Ectopic expression of WT or mutant <I>LRRK2</I> in dopaminergic neurons caused their significant loss accompanied by complex age-dependent changes in locomotor activity. Overall, the ubiquitous expression of <I>LRRK2</I> increased lifespan and fertility of the flies. However, these flies were more sensitive to rotenone. <I>LRRK2</I> expression in the eye exacerbated retinal degeneration. Importantly, in double transgenic flies, various indices of the eye and dopaminergic survival were modified in a complex fashion by a concomitant expression of <I>PINK1, DJ-1</I> or <I>Parkin</I>. This evidence suggests a genetic interaction between these PD-relevant genes.</p>
]]></description>
<dc:creator><![CDATA[Venderova, K., Kabbach, G., Abdel-Messih, E., Zhang, Y., Parks, R. J., Imai, Y., Gehrke, S., Ngsee, J., LaVoie, M. J., Slack, R. S., Rao, Y., Zhang, Z., Lu, B., Haque, M. E., Park, D. S.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp394</dc:identifier>
<dc:title><![CDATA[Leucine-rich repeat kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4404</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4390</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4405?rss=1">
<title><![CDATA[A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4405?rss=1</link>
<description><![CDATA[
<p>Duchenne muscular dystrophy (DMD) is caused by mutations in the <I>DMD</I> gene that abolish the synthesis of dystrophin protein. Antisense oligonucleotides (AOs) targeted to trigger excision of an exon bearing a mutant premature stop codon in the <I>DMD</I> transcript have been shown to skip the mutated exon and partially restore functional dystrophin protein in dystrophin-deficient <I>mdx</I> mice. To fully exploit the therapeutic potential of this method requires highly efficient systemic AO delivery to multiple muscle groups, to modify the disease process and restore muscle function. While systemic delivery of naked AOs in DMD animal models requires high doses and is of relatively poor efficiency, we and others have recently shown that short arginine-rich peptide-AO conjugates can dramatically improve <I>in vivo</I> DMD splice correction. Here we report for the first time that a chimeric fusion peptide (B-MSP-PMO) consisting of a muscle-targeting heptapeptide (MSP) fused to an arginine-rich cell-penetrating peptide (B-peptide) and conjugated to a morpholino oligomer (PMO) AO directs highly efficient systemic dystrophin splice correction in <I>mdx</I> mice. With very low systemic doses, we demonstrate that B-MSP-PMO restores high-level, uniform dystrophin protein expression in multiple peripheral muscle groups, yielding functional correction and improvement of the <I>mdx</I> dystrophic phenotype. Our data demonstrate proof-of-concept for this chimeric peptide approach in DMD splice correction therapy and is likely to have broad application.</p>
]]></description>
<dc:creator><![CDATA[Yin, H., Moulton, H. M., Betts, C., Seow, Y., Boutilier, J., Iverson, P. L., Wood, M. J.A.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp395</dc:identifier>
<dc:title><![CDATA[A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4414</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4405</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4415?rss=1">
<title><![CDATA[Identification of brain transcriptional variation reproduced in peripheral blood: an approach for mapping brain expression traits]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4415?rss=1</link>
<description><![CDATA[
<p>Genome-wide gene expression studies may provide substantial insight into gene activities and biological pathways differing between tissues and individuals. We investigated such gene expression variation by analyzing expression profiles in brain tissues derived from eight different brain regions and from blood in 12 monkeys from a biomedically important non-human primate model, the vervet (<I>Chlorocebus aethiops sabaeus</I>). We characterized brain regional differences in gene expression, focusing on transcripts for which inter-individual variation of expression in brain correlates well with variation in blood from the same individuals. Using stringent criteria, we identified 29 transcripts whose expression is measurable, stable, replicable, variable between individuals, relevant to brain function and heritable. Polymorphisms identified in probe regions could, in a minority of transcripts, confound the interpretation of the observed inter-individual variation. The high heritability of levels of these transcripts in a large vervet pedigree validated our approach of focusing on transcripts that showed higher inter-individual compared with intra-individual variation. These selected transcripts are candidate expression Quantitative Trait Loci, differentially regulating transcript levels in the brain among individuals. Given the high degree of conservation of tissue expression profiles between vervets and humans, our findings may facilitate the understanding of regional and individual transcriptional variation and its genetic mechanisms in humans. The approach employed here&mdash;utilizing higher quality tissue and more precise dissection of brain regions than is usually possible in humans&mdash;may therefore provide a powerful means to investigate variation in gene expression relevant to complex brain related traits, including human neuropsychiatric diseases.</p>
]]></description>
<dc:creator><![CDATA[Jasinska, A. J., Service, S., Choi, O.-w., DeYoung, J., Grujic, O., Kong, S.-y., Jorgensen, M. J., Bailey, J., Breidenthal, S., Fairbanks, L. A., Woods, R. P., Jentsch, J. D., Freimer, N. B.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp397</dc:identifier>
<dc:title><![CDATA[Identification of brain transcriptional variation reproduced in peripheral blood: an approach for mapping brain expression traits]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4427</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4415</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4428?rss=1">
<title><![CDATA[Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4428?rss=1</link>
<description><![CDATA[
<p>Tuberous sclerosis complex (TSC) is a genetic disorder linked to mutations of either the <I>TSC1</I> or <I>TSC2</I> gene, which encode proteins that form a complex to negatively regulate mammalian target of rapamycin complex 1 (mTORC1). Clinically, a small percentage of TSC patients develop severe infantile polycystic kidney disease (PKD), which is believed to be caused by deletion of the contiguous <I>TSC2</I> and <I>PKD1</I> genes on human chromosome 16. Recent studies have implicated the TSC/mTORC1 signaling pathway in PKD, but how dysfunction of the TSC/mTORC1 pathway induces PKD is not clear. We report a PKD mouse model created by knocking out <I>Tsc1</I> in a subset of renal tubular cells. Extensive renal cyst formation in these mice is accompanied by broadly elevated mTORC1 activity in both cell autonomous and non-cell autonomous compartments. Furthermore, cyst development requires mTORC1 activation, as low dosage of rapamycin administration effectively blocks cyst formation. Interestingly, disruption of <I>Pten</I>, an upstream regulator of TSC1/TSC2, in the same cells, does not lead to PKD seemingly due to limited activation of mTORC1, suggesting that PTEN may not be a major upstream regulator of TSC/mTORC1 during early postnatal kidney development.</p>
]]></description>
<dc:creator><![CDATA[Zhou, J., Brugarolas, J., Parada, L. F.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp398</dc:identifier>
<dc:title><![CDATA[Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4441</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4428</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4442?rss=1">
<title><![CDATA[Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4442?rss=1</link>
<description><![CDATA[
<p>Genome-wide association studies of breast cancer have identified multiple single nucleotide polymorphisms (SNPs) that are associated with increased breast cancer risks in the general population. In a previous study, we demonstrated that the minor alleles at three of these SNPs, in <I>FGFR2, TNRC9</I> and <I>MAP3K1</I>, also confer increased risks of breast cancer for <I>BRCA1</I> or <I>BRCA2</I> mutation carriers. Three additional SNPs rs3817198 at <I>LSP1</I>, rs13387042 at 2q35 and rs13281615 at 8q24 have since been reported to be associated with breast cancer in the general population, and in this study we evaluated their association with breast cancer risk in 9442 <I>BRCA1</I> and 5665 <I>BRCA2</I> mutation carriers from 33 study centres. The minor allele of rs3817198 was associated with increased breast cancer risk only for <I>BRCA2</I> mutation carriers [hazard ratio (HR) = 1.16, 95% CI: 1.07&ndash;1.25, <I>P</I>-trend = 2.8 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;4</sup>]. The best fit for the association of SNP rs13387042 at 2q35 with breast cancer risk was a dominant model for both <I>BRCA1</I> and <I>BRCA2</I> mutation carriers (<I>BRCA1</I>: HR = 1.14, 95% CI: 1.04&ndash;1.25, <I>P</I> = 0.0047; <I>BRCA2</I>: HR = 1.18 95% CI: 1.04&ndash;1.33, <I>P</I> = 0.0079). SNP rs13281615 at 8q24 was not associated with breast cancer for either <I>BRCA1</I> or <I>BRCA2</I> mutation carriers, but the estimated association for <I>BRCA2</I> mutation carriers (per-allele HR = 1.06, 95% CI: 0.98&ndash;1.14) was consistent with odds ratio estimates derived from population-based case&ndash;control studies. The <I>LSP1</I> and 2q35 SNPs appear to interact multiplicatively on breast cancer risk for <I>BRCA2</I> mutation carriers. There was no evidence that the associations vary by mutation type depending on whether the mutated protein is predicted to be stable or not.</p>
]]></description>
<dc:creator><![CDATA[Antoniou, A. C., Sinilnikova, O. M., McGuffog, L., Healey, S., Nevanlinna, H., Heikkinen, T., Simard, J., Spurdle, A. B., Beesley, J., Chen, X., The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Neuhausen, S. L., Ding, Y. C., Couch, F. J., Wang, X., Fredericksen, Z., Peterlongo, P., Peissel, B., Bonanni, B., Viel, A., Bernard, L., Radice, P., Szabo, C. I., Foretova, L., Zikan, M., Claes, K., Greene, M. H., Mai, P. L., Rennert, G., Lejbkowicz, F., Andrulis, I. L., Ozcelik, H., Glendon, G., OCGN, Gerdes, A.-M., Thomassen, M., Sunde, L., Caligo, M. A., Laitman, Y., Kontorovich, T., Cohen, S., Kaufman, B., Dagan, E., Baruch, R. G., Friedman, E., Harbst, K., Barbany-Bustinza, G., Rantala, J., Ehrencrona, H., Karlsson, P., Domchek, S. M., Nathanson, K. L., Osorio, A., Blanco, I., Lasa, A., Benitez, J., Hamann, U., Hogervorst, F. B.L., Rookus, M. A., Collee, J. M., Devilee, P., Ligtenberg, M. J., van der Luijt, R. B., Aalfs, C. M., Waisfisz, Q., Wijnen, J., van Roozendaal, C. E.P., HEBON, Peock, S., Cook, M., Frost, D., Oliver, C., Platte, R., Evans, D. G., Lalloo, F., Eeles, R., Izatt, L., Davidson, R., Chu, C., Eccles, D., Cole, T., Hodgson, S., EMBRACE, Godwin, A. K., Stoppa-Lyonnet, D., Buecher, B., Leone, M., Bressac-de Paillerets, B., Remenieras, A., Caron, O., Lenoir, G. M., Sevenet, N., Longy, M., Ferrer, S. F., Prieur, F., GEMO, Goldgar, D., Miron, A., John, E. M., Buys, S. S., Daly, M. B., Hopper, J. L., Terry, M. B., Yassin, Y., Breast Cancer Family Registry, Christian Singer, Gschwantler-Kaulich, D., Staudigl, C., Hansen, T. v. O., Barkardottir, R. B., Kirchhoff, T., Pal, P., Kosarin, K., Offit, K., Piedmonte, M., Rodriguez, G. C., Wakeley, K., Boggess, J. F., Basil, J., Schwartz, P. E., Blank, S. V., Toland, A. E., Montagna, M., Casella, C., Imyanitov, E. N., Allavena, A., Schmutzler, R. K., Versmold, B., Engel, C., Meindl, A., Ditsch, N., Arnold, N., Niederacher, D., Deissler, H., Fiebig, B., Suttner, C., Schonbuchner, I., Gadzicki, D., Caldes, T., de la Hoya, M., Pooley, K. A., Easton, D. F., Chenevix-Trench, G., on behalf of CIMBA.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp372</dc:identifier>
<dc:title><![CDATA[Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4456</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4442</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/22/4457?rss=1">
<title><![CDATA[A non-synonymous variant in ADH1B is strongly associated with prenatal alcohol use in a European sample of pregnant women]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/22/4457?rss=1</link>
<description><![CDATA[
<p>Pregnant women are advised to abstain from alcohol despite insufficient evidence on the fetal consequences of moderate prenatal alcohol use. Mendelian randomization could help distinguish causal effects from artifacts due to residual confounding and measurement errors; however, polymorphisms reliably associated with alcohol phenotypes are needed. We aimed to test whether alcohol dehydrogenase (<I>ADH</I>) gene variants were associated with alcohol use before and during pregnancy. Ten variants in four <I>ADH</I> genes were genotyped in women from South-West England. Phenotypes of interest were quantity and patterns of alcohol consumption before and during pregnancy, including quitting alcohol following pregnancy recognition. We tested single-locus associations between genotypes and phenotypes with regression models. We used Bayesian models (multi-locus) to take account of linkage disequilibrium and reanalyzed the data with further exclusions following two conservative definitions of &lsquo;white ethnicity&rsquo; based on the woman's reported parental ethnicity or a set of ancestry-informative genetic markers. Single-locus analyses on 7410 women of white/European background showed strong associations for rs1229984 (<I>ADH1B</I>). Rare allele carriers consumed less alcohol before pregnancy [odds ratio (OR) = 0.69; 95% confidence interval (CI): 0.56&ndash;0.86, <I>P</I> = 0.001], were less likely to have &lsquo;binged&rsquo; during pregnancy (OR = 0.55, 95% CI: 0.38&ndash;0.78, <I>P</I> = 0.0009), and more likely to have abstained in the first trimester of gestation (adjusted OR = 1.42, 95% CI: 1.12&ndash;1.80, <I>P</I> = 0.004). Multi-locus models confirmed these results. Sensitivity analyses did not suggest the presence of residual population stratification. We confirmed the established association of rs1229984 with reduced alcohol consumption over the life-course, contributing new evidence of an effect before and during pregnancy.</p>
]]></description>
<dc:creator><![CDATA[Zuccolo, L., Fitz-Simon, N., Gray, R., Ring, S. M., Sayal, K., Smith, G. D., Lewis, S. J.]]></dc:creator>
<dc:date>Fri, 23 Oct 2009 09:16:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp388</dc:identifier>
<dc:title><![CDATA[A non-synonymous variant in ADH1B is strongly associated with prenatal alcohol use in a European sample of pregnant women]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>22</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4466</prism:endingPage>
<prism:publicationDate>2009-11-15</prism:publicationDate>
<prism:startingPage>4457</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/NP?rss=1">
<title><![CDATA[Contents Page]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/NP?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:22 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp447</dc:identifier>
<dc:title><![CDATA[Contents Page]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/NP-a?rss=1">
<title><![CDATA[Cover Page]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/NP-a?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:22 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp449</dc:identifier>
<dc:title><![CDATA[Cover Page]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/NP-b?rss=1">
<title><![CDATA[Editorial Board]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/NP-b?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:22 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp451</dc:identifier>
<dc:title><![CDATA[Editorial Board]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/NP-c?rss=1">
<title><![CDATA[Subscription Page]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/NP-c?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:22 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp453</dc:identifier>
<dc:title><![CDATA[Subscription Page]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4013?rss=1">
<title><![CDATA[A gradient of ROR2 protein stability and membrane localization confers brachydactyly type B or Robinow syndrome phenotypes]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4013?rss=1</link>
<description><![CDATA[
<p>Mutations in ROR2 cause dominant brachydactyly type B (BDB1) or recessive Robinow syndrome (RRS), each characterized by a distinct combination of phenotypic features. We here report a novel nonsense mutation in ROR2 (c.1324C&gt;T; p.R441X) causing intracellular protein truncation in a patient exhibiting features of RRS in conjunction with severe recessive brachydactyly. The mutation is located at the same position as a previously described frame shift mutation causing dominant BDB1. To investigate the apparent discrepancy in phenotypic outcome, we analysed ROR2 protein stability and distribution in stably transfected cell lines expressing exact copies of several human RRS and BDB1 intracellular mutations. RRS mutant proteins were less abundant and retained intracellularly, although BDB1 mutants were stable and predominantly located at the cell membrane. The p.R441X mutation showed an intermediate pattern with membrane localization but also high endoplasmic reticulum retention. Furthermore, we observed a correlation between the severity of BDB1, the location of the mutation, and the amount of membrane-associated ROR2. Membrane protein fraction quantification revealed a gradient of distribution and stability correlating with the clinical phenotypes. This gradual model was confirmed by crossing mouse models for RRS and BDB1, yielding double heterozygous animals that exhibited an intermediate phenotype. We propose a model in which the RRS versus the BDB1 phenotype is determined by the relative degree of protein retention/degradation and the amount of mutant protein reaching the plasma membrane.</p>
]]></description>
<dc:creator><![CDATA[Schwarzer, W., Witte, F., Rajab, A., Mundlos, S., Stricker, S.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:22 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp345</dc:identifier>
<dc:title><![CDATA[A gradient of ROR2 protein stability and membrane localization confers brachydactyly type B or Robinow syndrome phenotypes]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4021</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4013</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4022?rss=1">
<title><![CDATA[LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4022?rss=1</link>
<description><![CDATA[
<p>Leucine rich repeat kinase 2 (<I>LRRK2</I>) mutations are the most common genetic cause of Parkinson's disease (PD) although LRRK2 function remains unclear. We report a new role for LRRK2 in regulating autophagy and describe the recruitment of LRRK2 to the endosomal&ndash;autophagic pathway and specific membrane subdomains. Using a novel human genomic reporter cellular model, we found LRRK2 to locate to membrane microdomains such as the neck of caveolae, microvilli/filopodia and intraluminal vesicles of multivesicular bodies (MVBs). In human brain and in cultured human cells LRRK2 was present in cytoplasmic puncta corresponding to MVBs and autophagic vacuoles (AVs). Expression of the common R1441C mutation from a genomic DNA construct caused impaired autophagic balance evident by the accumulation of MVBs and large AVs containing incompletely degraded material and increased levels of p62. Furthermore, the R1441C mutation induced the formation of skein-like abnormal MVBs. Conversely, LRRK2 siRNA knockdown increased autophagic activity and prevented cell death caused by inhibition of autophagy in starvation conditions. The work necessitated developing a new, more efficient recombineering strategy, which we termed Sequential insertion of Target with ovErlapping Primers (STEP) to seamlessly fuse the green fluorescent protein-derivative YPet to the human LRRK2 protein in the <I>LRRK2</I> genomic locus carried by a bacterial artificial chromosome. Taken together our data demonstrate the functional involvement of LRRK2 in the endosomal&ndash;autophagic pathway and the recruitment to specific membrane microdomains in a physiological human gene expression model suggesting a novel function for this important PD-related protein.</p>
]]></description>
<dc:creator><![CDATA[Alegre-Abarrategui, J., Christian, H., Lufino, M. M.P., Mutihac, R., Venda, L. L., Ansorge, O., Wade-Martins, R.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:22 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp346</dc:identifier>
<dc:title><![CDATA[LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4034</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4022</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4035?rss=1">
<title><![CDATA[p38 Mitogen-activated protein kinase stabilizes SMN mRNA through RNA binding protein HuR]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4035?rss=1</link>
<description><![CDATA[
<p>Spinal muscle atrophy (SMA) is an autosomal recessive neurodegenerative disease which is characterized by the loss of  motor neurons resulting in progressive muscle atrophy. Reduced amount of functional survival motor neuron (SMN) protein due to mutations or deletion in the <I>SMN1</I> gene is the cause of SMA. A potential treatment strategy for SMA is to upregulate levels of SMN protein originating from the <I>SMN2</I> gene compensating in part for the absence of functional <I>SMN1</I> gene. Although there exists a sizeable literature on <I>SMN2</I> inducing compounds, there is comparatively less known about the signaling pathways which modulate SMN levels. Here, we report a significant induction in SMN mRNA and protein following p38 activation by Anisomycin. We demonstrate that Anisomycin activation of p38 causes a rapid cytoplasmic accumulation of HuR, a RNA binding protein which binds to and stabilizes the AU-rich element within the SMN transcript. The stabilization of SMN mRNA, rather than transcriptional induction results in an increase in SMN protein. Our demonstration of SMN protein regulation through the p38 pathway and the role of HuR in this modulation may help in the identification and characterization of p38 pathway activators as potential therapeutic compounds for the treatment of SMA.</p>
]]></description>
<dc:creator><![CDATA[Farooq, F., Balabanian, S., Liu, X., Holcik, M., MacKenzie, A.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:22 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp352</dc:identifier>
<dc:title><![CDATA[p38 Mitogen-activated protein kinase stabilizes SMN mRNA through RNA binding protein HuR]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4045</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4035</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4046?rss=1">
<title><![CDATA[DNA methylation differences after exposure to prenatal famine are common and timing- and sex-specific]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4046?rss=1</link>
<description><![CDATA[
<p>Prenatal famine in humans has been associated with various later-life consequences, depending on the gestational timing of the insult and the sex of the exposed individual. Epigenetic mechanisms have been proposed to underlie these associations. Indeed, animal studies and our early human data on the imprinted <I>IGF2</I> locus indicated a link between prenatal nutritional and DNA methylation. However, it remains unclear how common changes in DNA methylation are and whether they are sex- and timing-specific paralleling the later-life consequences of prenatal famine exposure. To this end, we investigated the methylation of 15 loci implicated in growth and metabolic disease in individuals who were prenatally exposed to a war-time famine in 1944&ndash;45. Methylation of <I>INSIGF</I> was lower among individuals who were periconceptionally exposed to the famine (<I>n</I> = 60) compared with their unexposed same-sex siblings (<I>P</I> = 2 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;5</sup>), whereas methylation of <I>IL10</I>, <I>LEP</I>, <I>ABCA1</I>, <I>GNASAS</I> and <I>MEG3</I> was higher (all <I>P</I> &lt; 10<sup>&ndash;3</sup>). A significant interaction with sex was observed for <I>INSIGF</I>, <I>LEP</I> and <I>GNASAS</I>. Next, methylation of eight representative loci was compared between 62 individuals exposed late in gestation and their unexposed siblings. Methylation was different for <I>GNASAS</I> (<I>P</I> = 1.1 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;7</sup>) and, in men, <I>LEP</I> (<I>P</I> = 0.017). Our data indicate that persistent changes in DNA methylation may be a common consequence of prenatal famine exposure and that these changes depend on the sex of the exposed individual and the gestational timing of the exposure.</p>
]]></description>
<dc:creator><![CDATA[Tobi, E. W., Lumey, L.H., Talens, R. P., Kremer, D., Putter, H., Stein, A. D., Slagboom, P. E., Heijmans, B. T.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:23 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp353</dc:identifier>
<dc:title><![CDATA[DNA methylation differences after exposure to prenatal famine are common and timing- and sex-specific]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4053</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4046</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4054?rss=1">
<title><![CDATA[The DNA methylome of pediatric acute lymphoblastic leukemia]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4054?rss=1</link>
<description><![CDATA[
<p>Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with high hyperdiploidy [51&ndash;67 chromosomes] and the t(12;21)(p13;q22) [<I>ETV6/RUNX1</I> fusion] representing the most frequent abnormalities. Although these arise <I>in utero</I>, there is long latency before overt ALL, showing that additional changes are needed. Gene dysregulation through hypermethylation may be such an event; however, this has not previously been investigated in a detailed fashion. We performed genome-wide methylation profiling using bacterial artificial chromosome arrays and promoter-specific analyses of high hyperdiploid and <I>ETV6/RUNX1</I>-positive ALLs. In addition, global gene expression analyses were performed to identify associated expression patterns. Unsupervised cluster and principal component analyses of the chromosome-wide methylome profiles could successfully subgroup the two genetic ALL types. Analysis of all currently known promoter-specific CpG islands demonstrated that several B-cell- and neoplasia-associated genes were hypermethylated and underexpressed, indicating that aberrant methylation plays a significant leukemogenic role. Interestingly, methylation hotspots were associated with chromosome bands predicted to harbor imprinted genes and the tri-/tetrasomic chromosomes in the high hyperdiploid ALLs were less methylated than their disomic counterparts. Decreased methylation of gained chromosomes is a previously unknown phenomenon that may have ramifications not only for the pathogenesis of high hyperdiploid ALL but also for other disorders with acquired or constitutional numerical chromosome anomalies.</p>
]]></description>
<dc:creator><![CDATA[Davidsson, J., Lilljebjorn, H., Andersson, A., Veerla, S., Heldrup, J., Behrendtz, M., Fioretos, T., Johansson, B.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:23 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp354</dc:identifier>
<dc:title><![CDATA[The DNA methylome of pediatric acute lymphoblastic leukemia]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4065</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4054</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4066?rss=1">
<title><![CDATA[Molecular correlates of axonal and synaptic pathology in mouse models of Batten disease]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4066?rss=1</link>
<description><![CDATA[
<p>Neuronal ceroid lipofuscinoses (NCLs; Batten disease) are collectively the most frequent autosomal-recessive neurodegenerative disease of childhood, but the underlying cellular and molecular mechanisms remain unclear. Several lines of evidence have highlighted the important role that non-somatic compartments of neurons (axons and synapses) play in the instigation and progression of NCL pathogenesis. Here, we report a progressive breakdown of axons and synapses in the brains of two different mouse models of NCL: <I>Ppt1</I><sup><I>&ndash;/&ndash;</I></sup> model of infantile NCL and <I>Cln6</I><sup><I>nclf</I></sup> model of variant late-infantile NCL. Synaptic pathology was evident in the thalamus and cortex of these mice, but occurred much earlier within the thalamus. Quantitative comparisons of expression levels for a subset of proteins previously implicated in regulation of axonal and synaptic vulnerability revealed changes in proteins involved with synaptic function/stability and cell-cycle regulation in both strains of NCL mice. Protein expression changes were present at pre/early-symptomatic stages, occurring in advance of morphologically detectable synaptic or axonal pathology and again displayed regional selectivity, occurring first within the thalamus and only later in the cortex. Although significant differences in individual protein expression profiles existed between the two NCL models studied, 2 of the 15 proteins examined (VDAC1 and Pttg1) displayed robust and significant changes at pre/early-symptomatic time-points in both models. Our study demonstrates that synapses and axons are important early pathological targets in the NCLs and has identified two proteins, VDAC1 and Pttg1, with the potential for use as <I>in vivo</I> biomarkers of pre/early-symptomatic axonal and synaptic vulnerability in the NCLs.</p>
]]></description>
<dc:creator><![CDATA[Kielar, C., Wishart, T. M., Palmer, A., Dihanich, S., Wong, A. M., Macauley, S. L., Chan, C.-H., Sands, M. S., Pearce, D. A., Cooper, J. D., Gillingwater, T. H.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:23 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp355</dc:identifier>
<dc:title><![CDATA[Molecular correlates of axonal and synaptic pathology in mouse models of Batten disease]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4080</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4066</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4081?rss=1">
<title><![CDATA[The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4081?rss=1</link>
<description><![CDATA[
<p>Genome-wide association studies have identified a number of signals for both Type 2 Diabetes and related quantitative traits. For the majority of loci, the transition from association signal to mutational mechanism has been difficult to establish. Glucokinase (GCK) regulates glucose storage and disposal in the liver where its activity is regulated by glucokinase regulatory protein (GKRP; gene name <I>GCKR</I>). Fructose-6 and fructose-1 phosphate (F6P and F1P) enhance or reduce GKRP-mediated inhibition, respectively. A common <I>GCKR</I> variant <I>(</I>P446L) is reproducibly associated with triglyceride and fasting plasma glucose levels in the general population. The aim of this study was to determine the mutational mechanism responsible for this genetic association. Recombinant human GCK and both human wild-type (WT) and P446L-GKRP proteins were generated. GCK kinetic activity was observed spectrophotometrically using an NADP<sup>+</sup>-coupled assay. WT and P446L-GKRP-mediated inhibition of GCK activity and subsequent regulation by phosphate esters were determined. Assays matched for GKRP activity demonstrated no difference in dose-dependent inhibition of GCK activity or F1P-mediated regulation. However, the response to physiologically relevant F6P levels was significantly attenuated with P446L-GKRP (<I>n</I> = 18; <I>P</I> &le; 0.03). Experiments using equimolar concentrations of both regulatory proteins confirmed these findings (<I>n</I> = 9; <I>P</I> &lt; 0.001). In conclusion, P446L-GKRP has reduced regulation by physiological concentrations of F6P, resulting indirectly in increased GCK activity. Altered GCK regulation in liver is predicted to enhance glycolytic flux, promoting hepatic glucose metabolism and elevating concentrations of malonyl-CoA, a substrate for <I>de novo</I> lipogenesis, providing a mutational mechanism for the reported association of this variant with raised triglycerides and lower glucose levels.</p>
]]></description>
<dc:creator><![CDATA[Beer, N. L., Tribble, N. D., McCulloch, L. J., Roos, C., Johnson, P. R.V., Orho-Melander, M., Gloyn, A. L.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:23 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp357</dc:identifier>
<dc:title><![CDATA[The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4088</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4081</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4089?rss=1">
<title><![CDATA[Evaluation of the therapeutic potential of carbonic anhydrase inhibitors in two animal models of dystrophin deficient muscular dystrophy]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4089?rss=1</link>
<description><![CDATA[
<p>Duchenne Muscular Dystrophy is an inherited muscle degeneration disease for which there is still no efficient treatment. However, compounds active on the disease may already exist among approved drugs but are difficult to identify in the absence of cellular models. We used the <I>Caenorhabditis elegans</I> animal model to screen a collection of 1000 already approved compounds. Two of the most active hits obtained were methazolamide and dichlorphenamide, carbonic anhydrase inhibitors widely used in human therapy. In <I>C. elegans</I>, these drugs were shown to interact with CAH-4, a putative carbonic anhydrase. The therapeutic efficacy of these compounds was further validated in long-term experiments on <I>mdx</I> mice, the mouse model of Duchenne Muscular Dystrophy. Mice were treated for 120 days with food containing methazolamide or dichlorphenamide at two doses each. <I>Musculus tibialis anterior</I> and diaphragm muscles were histologically analyzed and isometric muscle force was measured in <I>M. extensor digitorum longus</I>. Both substances increased the tetanic muscle force in the treated <I>M. extensor digitorum longus</I> muscle group, dichlorphenamide increased the force significantly by 30%, but both drugs failed to increase resistance of muscle fibres to eccentric contractions. Histological analysis revealed a reduction of centrally nucleated fibers in <I>M. tibialis anterior</I> and diaphragm in the treated groups. These studies further demonstrated that a <I>C. elegans</I>-based screen coupled with a mouse model validation strategy can lead to the identification of potential pharmacological agents for rare diseases.</p>
]]></description>
<dc:creator><![CDATA[Giacomotto, J., Pertl, C., Borrel, C., Walter, M. C., Bulst, S., Johnsen, B., Baillie, D. L., Lochmuller, H., Thirion, C., Segalat, L.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:23 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp358</dc:identifier>
<dc:title><![CDATA[Evaluation of the therapeutic potential of carbonic anhydrase inhibitors in two animal models of dystrophin deficient muscular dystrophy]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4101</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4089</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4102?rss=1">
<title><![CDATA[Aprataxin, poly-ADP ribose polymerase 1 (PARP-1) and apurinic endonuclease 1 (APE1) function together to protect the genome against oxidative damage]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4102?rss=1</link>
<description><![CDATA[
<p>Aprataxin, defective in the neurodegenerative disorder ataxia oculomotor apraxia type 1 (AOA1), is a DNA repair protein that processes the product of abortive ligations, 5' adenylated DNA. In addition to its interaction with the single-strand break repair protein XRCC1, aprataxin also interacts with poly-ADP ribose polymerase 1 (PARP-1), a key player in the detection of DNA single-strand breaks. Here, we reveal reduced expression of PARP-1, apurinic endonuclease 1 (APE1) and OGG1 in AOA1 cells and demonstrate a requirement for PARP-1 in the recruitment of aprataxin to sites of DNA breaks. While inhibition of PARP activity did not affect aprataxin activity <I>in vitro</I>, it retarded its recruitment to sites of DNA damage <I>in vivo</I>. We also demonstrate the presence of elevated levels of oxidative DNA damage in AOA1 cells coupled with reduced base excision and gap filling repair efficiencies indicative of a synergy between aprataxin, PARP-1, APE-1 and OGG1 in the DNA damage response. These data support both direct and indirect modulating functions for aprataxin on base excision repair.</p>
]]></description>
<dc:creator><![CDATA[Harris, J. L., Jakob, B., Taucher-Scholz, G., Dianov, G. L., Becherel, O. J., Lavin, M. F.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:23 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp359</dc:identifier>
<dc:title><![CDATA[Aprataxin, poly-ADP ribose polymerase 1 (PARP-1) and apurinic endonuclease 1 (APE1) function together to protect the genome against oxidative damage]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4117</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4102</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4118?rss=1">
<title><![CDATA[Copy number variation influences gene expression and metabolic traits in mice]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4118?rss=1</link>
<description><![CDATA[
<p>Copy number variants (CNVs) are genomic segments which are duplicated or deleted among different individuals. CNVs have been implicated in both Mendelian and complex traits, including immune and behavioral disorders, but the study of the mechanisms by which CNVs influence gene expression and clinical phenotypes in humans is complicated by the limited access to tissues and by population heterogeneity. We now report studies of the effect of 19 CNVs on gene expression and metabolic traits in a mouse intercross between strains C57BL/6J and C3H/HeJ. We found that 83% of genes predicted to occur within CNVs were differentially expressed. The expression of most CNV genes was correlated with copy number, but we also observed evidence that gene expression was altered in genes flanking CNVs, suggesting that CNVs may contain regulatory elements for these genes. Several CNVs mapped to hotspots, genomic regions influencing expression of tens or hundreds of genes. Several metabolic traits including cholesterol, triglycerides, glucose and body weight mapped to three CNVs in the genome, in mouse chromosomes 1, 4 and 17. Predicted CNV genes, such as <I>Itlna</I>, <I>Defcr-1</I>, <I>Trim12</I> and <I>Trim34</I> were highly correlated with these traits. Our results suggest that CNVs have a significant impact on gene expression and that CNVs may be playing a role in the mechanisms underlying metabolic traits in mice.</p>
]]></description>
<dc:creator><![CDATA[Orozco, L. D., Cokus, S. J., Ghazalpour, A., Ingram-Drake, L., Wang, S., van Nas, A., Che, N., Araujo, J. A., Pellegrini, M., Lusis, A. J.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:23 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp360</dc:identifier>
<dc:title><![CDATA[Copy number variation influences gene expression and metabolic traits in mice]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4129</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4118</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4130?rss=1">
<title><![CDATA[Depletion of zebrafish Tcap leads to muscular dystrophy via disrupting sarcomere-membrane interaction, not sarcomere assembly]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4130?rss=1</link>
<description><![CDATA[
<p>Tcap/telethonin encodes a Z-disc protein that plays important roles in sarcomere assembly, sarcomere-membrane interaction and stretch sensing. It remains unclear why mutations in Tcap lead to limb-girdle muscular dystrophy 2G (LGMD2G) in human patients. Here, we cloned <I>tcap</I> in zebrafish and conducted genetic studies. We show that <I>tcap</I> is functionally conserved, as the Tcap protein appears in the sarcomeric Z-disc and reduction of Tcap resulted in muscular dystrophy-like phenotypes including deformed muscle structure and impaired swimming ability. However, the observations that Tcap integrates into the sarcomere at a stage after the Z-disc becomes periodic, and that the sarcomere remains intact in <I>tcap</I> morphants, suggest that defective sarcomere assembly does not contribute to this particular type of muscular dystrophy. Instead, a defective interaction between the sarcomere and plasma membrane was detected, which was further underscored by the disrupted development of the T-tubule system. Pertinent to a potential function in stretch sensor signaling, zebrafish <I>tcap</I> exhibits a variable expression pattern during somitogenesis. The variable expression is inducible by stretch force, and the expression level of Tcap is negatively regulated by integrin-link kinase (ILK), a protein kinase that is involved in stretch sensing signaling. Together, our genetic studies of <I>tcap</I> in zebrafish suggested that pathogenesis in LGMD2G is due to a disruption of sarcomere&ndash;T-tubular interaction, but not of sarcomere assembly <I>per se</I>. In addition, our data prompted a novel hypothesis that predicts that the transcription level of Tcap can be regulated by the stretch force to ensure proper sarcomere&ndash;membrane interaction in striated muscles.</p>
]]></description>
<dc:creator><![CDATA[Zhang, R., Yang, J., Zhu, J., Xu, X.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:23 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp362</dc:identifier>
<dc:title><![CDATA[Depletion of zebrafish Tcap leads to muscular dystrophy via disrupting sarcomere-membrane interaction, not sarcomere assembly]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4140</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4130</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4141?rss=1">
<title><![CDATA[Transcriptional dysregulation of TrkA associates with neurodegeneration in spinocerebellar ataxia type 17]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4141?rss=1</link>
<description><![CDATA[
<p>TATA binding protein (TBP), a universal transcription factor, is broadly required by nuclear RNA polymerases for the initiation of transcription. TBP contains a polymorphic polyglutamine tract in its N-terminal region, and expansion of this tract leads to spinocerebellar ataxia type 17 (SCA17), one of nine dominantly inherited neurodegenerative diseases caused by polyglutamine expansion in the affected proteins. The expanded polyglutamine proteins are ubiquitously expressed, but cause selective and characteristic neurodegeneration in distinct brain regions in each disease. Unlike many other polyglutamine proteins, whose functions are not yet fully understood, TBP is a well-characterized transcription factor that is restricted to the nucleus. Thus, investigating how mutant TBP mediates neuropathology should help elucidate the mechanisms by which transcriptional dysregulation contributes to neuronal dysfunction and/or neurodegeneration in polyglutamine diseases. To this end, we characterized cellular and mouse models expressing polyQ-expanded TBP. The cell model exhibits characteristic features of neuronal dysfunction, including decreased cell viability and defective neurite outgrowth. We found that the high-affinity nerve growth factor receptor, TrkA, is down-regulated by mutant TBP in cells. Down-regulation of TrkA also occurs in the cerebellum of SCA17 transgenic mice prior to Purkinje cell degeneration. Mutant TBP binds more Sp1, reduces its occupancy of the <I>TrkA</I> promoter and inhibits the activity of the <I>TrkA</I> promoter. These findings suggest that the transcriptional down-regulation of TrkA by mutant TBP contributes to SCA17 pathogenesis.</p>
]]></description>
<dc:creator><![CDATA[Shah, A. G., Friedman, M. J., Huang, S., Roberts, M., Li, X.-J., Li, S.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:23 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp363</dc:identifier>
<dc:title><![CDATA[Transcriptional dysregulation of TrkA associates with neurodegeneration in spinocerebellar ataxia type 17]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4152</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4141</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4153?rss=1">
<title><![CDATA[Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4153?rss=1</link>
<description><![CDATA[
<p>Aggregation and cleavage are two hallmarks of Tau pathology in Alzheimer disease (AD), and abnormal fragmentation of Tau is thought to contribute to the nucleation of Tau paired helical filaments. Clearance of the abnormally modified protein could occur by the ubiquitin&ndash;proteasome and autophagy&ndash;lysosomal pathways, the two major routes for protein degradation in cells. There is a debate on which of these pathways contributes to clearance of Tau protein and of the abnormal Tau aggregates formed in AD. Here, we demonstrate in an inducible neuronal cell model of tauopathy that the autophagy&ndash;lysosomal system contributes to both Tau fragmentation into pro-aggregating forms and to clearance of Tau aggregates. Inhibition of macroautophagy enhances Tau aggregation and cytotoxicity. The Tau repeat domain can be cleaved near the N terminus by a cytosolic protease to generate the fragment F1. Additional cleavage near the C terminus by the lysosomal protease cathepsin L is required to generate Tau fragments F2 and F3 that are highly amyloidogenic and capable of seeding the aggregation of Tau. We identify in this work that components of a selective form of autophagy, chaperone-mediated autophagy, are involved in the delivery of cytosolic Tau to lysosomes for this limited cleavage. However, F1 does not fully enter the lysosome but remains associated with the lysosomal membrane. Inefficient translocation of the Tau fragments across the lysosomal membrane seems to promote formation of Tau oligomers at the surface of these organelles which may act as precursors of aggregation and interfere with lysosomal functioning.</p>
]]></description>
<dc:creator><![CDATA[Wang, Y., Martinez-Vicente, M., Kruger, U., Kaushik, S., Wong, E., Mandelkow, E.-M., Cuervo, A. M., Mandelkow, E.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:23 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp367</dc:identifier>
<dc:title><![CDATA[Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4170</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4153</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4171?rss=1">
<title><![CDATA[Tbx22null mice have a submucous cleft palate due to reduced palatal bone formation and also display ankyloglossia and choanal atresia phenotypes]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4171?rss=1</link>
<description><![CDATA[
<p>Craniofacial defects involving the lip and/or palate are among the most common human birth defects. X-linked cleft palate and ankyloglossia results from loss-of-function mutations in the gene encoding the T-box transcription factor TBX22. Further studies show that <I>TBX22</I> mutations are also found in around 5% of non-syndromic cleft palate patients. Although palate defects are obvious at birth, the underlying developmental pathogenesis remains unclear. Here, we report a <I>Tbx22</I><sup><I>null</I></sup> mouse, which has a submucous cleft palate (SMCP) and ankyloglossia, similar to the human phenotype, with a small minority showing overt clefts. We also find persistent oro-nasal membranes or, in some mice a partial rupture, resulting in choanal atresia. Each of these defects can cause severe breathing and/or feeding difficulties in the newborn pups, which results in ~50% post-natal lethality. Analysis of the craniofacial skeleton demonstrates a marked reduction in bone formation in the posterior hard palate, resulting in the classic notch associated with SMCP. Our results suggest that <I>Tbx22</I> plays an important role in the osteogenic patterning of the posterior hard palate. Ossification is severely reduced after condensation of the palatal mesenchyme, resulting from a delay in the maturation of osteoblasts. Rather than having a major role in palatal shelf closure, we show that <I>Tbx22</I> is an important determinant for intramembranous bone formation in the posterior hard palate, which underpins normal palate development and function. These findings could have important implications for the molecular diagnosis in patients with isolated SMCP and/or unexplained choanal atresia.</p>
]]></description>
<dc:creator><![CDATA[Pauws, E., Hoshino, A., Bentley, L., Prajapati, S., Keller, C., Hammond, P., Martinez-Barbera, J.-P., Moore, G. E., Stanier, P.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:23 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp368</dc:identifier>
<dc:title><![CDATA[Tbx22null mice have a submucous cleft palate due to reduced palatal bone formation and also display ankyloglossia and choanal atresia phenotypes]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4179</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4171</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4180?rss=1">
<title><![CDATA[A conserved role for the mitochondrial citrate transporter Sea/SLC25A1 in the maintenance of chromosome integrity]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4180?rss=1</link>
<description><![CDATA[
<p>Histone acetylation plays essential roles in cell cycle progression, DNA repair, gene expression and silencing. Although the knowledge regarding the roles of acetylation of histone lysine residues is rapidly growing, very little is known about the biochemical pathways providing the nucleus with metabolites necessary for physiological chromatin acetylation. Here, we show that mutations in the <I>scheggia (sea)-</I>encoded Sea protein, the <I>Drosophila</I> ortholog of the human mitochondrial citrate carrier <I>Solute carrier 25 A1</I> (<I>SLC25A1</I>), impair citrate transport from mitochondria to the cytosol. Interestingly, inhibition of <I>sea</I> expression results in extensive chromosome breakage in mitotic cells and induces an ATR-dependent cell cycle arrest associated with a dramatic reduction of global histone acetylation. Notably, loss of <I>SLC25A1</I> in short interfering RNA (siRNA)-treated human primary fibroblasts also leads to chromosome breaks and histone acetylation defects, suggesting an evolutionary conserved role for Sea/SLC25A1 in the regulation of chromosome integrity. This study therefore provides an intriguing and unexpected link between intermediary metabolism and epigenetic control of genome stability.</p>
]]></description>
<dc:creator><![CDATA[Morciano, P., Carrisi, C., Capobianco, L., Mannini, L., Burgio, G., Cestra, G., De Benedetto, G. E., Corona, D. F.V., Musio, A., Cenci, G.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:23 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp370</dc:identifier>
<dc:title><![CDATA[A conserved role for the mitochondrial citrate transporter Sea/SLC25A1 in the maintenance of chromosome integrity]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4188</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4180</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4189?rss=1">
<title><![CDATA[A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4189?rss=1</link>
<description><![CDATA[
<p>Numerous single nucleotide polymorphisms (SNPs) have been found in recent genome wide association studies (GWAS) to be associated with subtle plasma triglyceride (TG) variation in normolipidemic subjects. However, since these GWAS did not specifically evaluate patients with rare disorders of lipoprotein metabolism&mdash;&lsquo;hyperlipoproteinemia&rsquo; (HLP)&mdash;it remains largely unresolved whether any of these SNP determinants of modest physiological changes in TG are necessarily also determinants of most HLP phenotypes. To address this question, we evaluated 28 TG-associated SNPs from GWAS in 386 unrelated adult patients with one of five Fredrickson phenotypes (HLP types 2A, 2B, 3, 4 and 5) and 242 matched normolipidemic controls. We found that several SNPs associated with TG in normolipidemic samples, including <I>APOA5</I> p.S19W and -1131T&gt;C, <I>TRIB1</I> rs17321515, <I>TBL2</I> rs17145738, <I>GCKR</I> rs780094, <I>GALNT2</I> rs4846914 and <I>ANGPTL3</I> rs12130333, were significantly associated with HLP types 2B, 3, 4 and 5. The findings indicate that: (i) the TG-associated Fredrickson HLP types 2B, 3, 4 and 5 are polygenic traits; (ii) these Fredrickson HLP types share numerous genetic determinants among themselves; and (iii) genetic determinants of modest TG variation in normolipidemic population samples also underlie&mdash;to an apparently even greater degree&mdash;susceptibility to these rare HLP phenotypes. Thus, the TG-associated Fredrickson HLP types 2B, 3, 4 and 5, although historically considered to be distinct are actually complex traits sharing among them several common genetic determinants seen in GWAS of normolipidemic population samples.</p>
]]></description>
<dc:creator><![CDATA[Hegele, R. A., Ban, M. R., Hsueh, N., Kennedy, B. A., Cao, H., Zou, G. Y., Anand, S., Yusuf, S., Huff, M. W., Wang, J.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:23 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp361</dc:identifier>
<dc:title><![CDATA[A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4194</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4189</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4195?rss=1">
<title><![CDATA[Common and different genetic background for rheumatoid arthritis and coeliac disease]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4195?rss=1</link>
<description><![CDATA[
<p>Recent genome-wide association studies (GWAS) have revealed genetic risk factors in autoimmune and inflammatory disorders. Several of the associated genes and underlying pathways are shared by various autoimmune diseases. Rheumatoid arthritis (RA) and coeliac disease (CD) are two autoimmune disorders which have commonalities in their pathogenesis. We aimed to replicate known RA loci in a Dutch RA population, and to investigate whether the effect of known RA and CD risk factors generalize across the two diseases. We selected all loci associated to either RA or CD in a GWAS and confirmed in an independent cohort, with a combined <I>P</I>-value cut-off <I>P</I> &lt; 5 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;6</sup>. We genotyped 11 RA and 11 CD loci in 1368 RA patients, 795 CD patients and 1683 Dutch controls. We combined our results in a meta-analysis with UK GWAS on RA (1860 cases; 2938 controls) and CD (767 cases; 1422 controls). In the Dutch RA cohort, the <I>PTPN22</I> and <I>IL2/IL21</I> variants showed convincing association (<I>P</I> = 3.4 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;12</sup> and <I>P</I> = 2.8 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;4</sup>, respectively). Association of RA with the known CD risk variant in the <I>SH2B3</I> was also observed, predominantly in the subgroup of rheumatoid factor-positive RA patients (<I>P</I> = 0.0055). In a meta-analysis of Dutch and UK data sets, shared association with six loci (<I>TNFAIP3</I>, <I>IL2/IL21</I>, <I>SH2B3</I>, <I>LPP, MMEL1/TNFRSF14</I> and <I>PFKFB3/PRKCQ</I>) was observed in both RA and CD cohorts. We confirmed two known loci and identified four novel ones for shared CD&ndash;RA genetic risk. Most of the shared loci further emphasize a role for adaptive and innate immunity in these diseases.</p>
]]></description>
<dc:creator><![CDATA[Coenen, M. J.H., Trynka, G., Heskamp, S., Franke, B., van Diemen, C. C., Smolonska, J., van Leeuwen, M., Brouwer, E., Boezen, M. H., Postma, D. S., Platteel, M., Zanen, P., Lammers, J.-W. W.J., Groen, H. J.M., Mali, W. P.T.M., Mulder, C. J., Tack, G. J., Verbeek, W. H.M., Wolters, V. M., Houwen, R. H.J., Mearin, M. L., van Heel, D. A., Radstake, T. R.D.J., van Riel, P. L.C.M., Wijmenga, C., Barrera, P., Zhernakova, A.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:23 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp365</dc:identifier>
<dc:title><![CDATA[Common and different genetic background for rheumatoid arthritis and coeliac disease]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4203</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4195</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4204?rss=1">
<title><![CDATA[Investigating the genetic association between ERAP1 and ankylosing spondylitis]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4204?rss=1</link>
<description><![CDATA[
<p>A strong association between <I>ERAP1</I> and ankylosing spondylitis (AS) was recently identified by the Wellcome Trust Case Control Consortium and the Australo-Anglo-American Spondylitis Consortium (WTCCC-TASC) study. <I>ERAP1</I> is highly polymorphic with strong linkage disequilibrium evident across the gene. We therefore conducted a series of experiments to try to identify the primary genetic association(s) with <I>ERAP1</I>. We replicated the original associations in an independent set of 730 patients and 1021 controls, resequenced <I>ERAP1</I> to define the full extent of coding polymorphisms and tested all variants in additional association studies. The genetic association with <I>ERAP1</I> was independently confirmed; the strongest association was with rs30187 in the replication set (<I>P</I> = 3.4 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;3</sup>). When the data were combined with the original WTCCC-TASC study the strongest association was with rs27044 (<I>P</I> = 1.1 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;9</sup>). We identified 33 sequence polymorphisms in <I>ERAP1</I>, including three novel and eight known non-synonymous polymorphisms. We report several new associations between AS and polymorphisms distributed across <I>ERAP1</I> from the extended case&ndash;control study, the most significant of which was with rs27434 (<I>P</I> = 4.7 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;7</sup>). Regression analysis failed to identify a primary association clearly; we therefore used data from HapMap to impute genotypes for an additional 205 non-coding SNPs located within and adjacent to <I>ERAP1</I>. A number of highly significant associations (<I>P</I> &lt; 5 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;9</sup>) were identified in regulatory sequences which are good candidates for causing susceptibility to AS, possibly by regulating <I>ERAP1</I> expression.</p>
]]></description>
<dc:creator><![CDATA[Harvey, D., Pointon, J. J., Evans, D. M., Karaderi, T., Farrar, C., Appleton, L. H., Sturrock, R. D., Stone, M. A., Oppermann, U., Brown, M. A., Wordsworth, B. P.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:23 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp371</dc:identifier>
<dc:title><![CDATA[Investigating the genetic association between ERAP1 and ankylosing spondylitis]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4212</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4204</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4213?rss=1">
<title><![CDATA[Genetic variation in NOS1AP is associated with sudden cardiac death: evidence from the Rotterdam Study]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4213?rss=1</link>
<description><![CDATA[
<p>Common variation within the nitric oxide-1 synthase activator protein (<I>NOS1AP</I>) locus is strongly related to QT interval, a sudden cardiac death (SCD) risk factor. A recent report describes common variation in <I>NOS1AP</I> associated with SCD in a US population of European ancestry. The objective of the current study was to obtain additional evidence by investigating the association between <I>NOS1AP</I> variants and SCD in the prospective population-based Rotterdam Study. The study population consisted of 5974 European ancestry subjects, aged 55 years and older, genotyped on Illumina arrays. SCD was defined according to European Society of Cardiology guidelines. Smoking, body mass index, diabetes mellitus, hypertension, heart failure and myocardial infarction were used as covariates in Cox proportional hazard models. Results were combined with reported evidence using inverse-variance weighted meta-analysis. Two hundred and eight (109 witnessed) cases of SCD occurred during a mean follow-up of 10.4 years. Within the Rotterdam Study alone, no significant associations were observed. Upon pooling of results with existing data, we observed strengthening of existing evidence for rs16847549 (US data HR = 1.31, <I>P</I> = 0.0024; Rotterdam Study HR = 1.18, <I>P</I> = 0.16; joint HR = 1.26, <I>P</I> = 0.0011). When the case definition in the Rotterdam Study was restricted to witnessed SCD, association of rs16847549 with SCD became stronger (joint <I>P</I> = 0.00019) and additionally the association between rs12567209 and SCD gained significance (US data HR = 0.57, <I>P</I> = 0.0035; Rotterdam Study HR = 0.69, <I>P</I> = 0.23; joint HR = 0.60, <I>P</I> = 0.0018). In conclusion, this study provided additional evidence for association between genetic variation within <I>NOS1AP</I> and SCD. The mechanism by which this effect is exerted remains to be elucidated.</p>
]]></description>
<dc:creator><![CDATA[Eijgelsheim, M., Newton-Cheh, C., Aarnoudse, A. L.H.J., van Noord, C., Witteman, J. C.M., Hofman, A., Uitterlinden, A. G., Stricker, B. H.C.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:23 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp356</dc:identifier>
<dc:title><![CDATA[Genetic variation in NOS1AP is associated with sudden cardiac death: evidence from the Rotterdam Study]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4218</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4213</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4219?rss=1">
<title><![CDATA[Replication of celiac disease UK genome-wide association study results in a US population]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4219?rss=1</link>
<description><![CDATA[
<p>Celiac disease is a common disease with a prevalence of ~1%. A recent genome-wide association study (GWAS) and follow-up study identified eight loci significantly associated with celiac disease risk. We genotyped the top 1020 non-HLA single nucleotide polymorphisms (SNPs) from the GWAS study that were genotyped in the previous follow-up study. After quality control assessments, 975 SNPs were analyzed for association with 906 celiac disease cases and 3819 controls, using logistic regression. Additional genotype data were generated by imputation and analyzed across the regions showing the strongest statistical evidence for association. Twenty SNPs were associated with celiac disease with <I>P</I> &lt; 0.01 in the current study as well as in the previous follow-up study, of which 16 had <I>P</I> &lt; 0.001 and 11 had <I>P</I> &lt; 1 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;11</sup>. Five of eight regions identified in the follow-up study were strongly associated with celiac disease, including regions on 1q31, 3q25, 3q28, 4q27 and 12q24. The strongest associations were at 4q27, the region most strongly associated in the GWAS and follow-up study and containing <I>IL2</I> and <I>IL21</I>, and at 3q28 harboring <I>LPP</I>. In addition, we provide new evidence for an association, not previously reported, on 2q31 harboring a strong candidate gene, <I>ITGA4</I>. In conclusion, in this first follow-up study of celiac cases from the USA, we provide additional evidence that five of eight previously identified regions harbor risk alleles for celiac disease, and new evidence for an association on 2q31. The underlying functional mutations responsible for these replicated associations need to be identified.</p>
]]></description>
<dc:creator><![CDATA[Garner, C.P., Murray, J.A., Ding, Y.C., Tien, Z., van Heel, D.A., Neuhausen, S.L.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:24 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp364</dc:identifier>
<dc:title><![CDATA[Replication of celiac disease UK genome-wide association study results in a US population]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4225</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4219</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/21/4226?rss=1">
<title><![CDATA[Genetic and physical interaction between the NPHP5 and NPHP6 gene products]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/21/4226?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Schafer, T., Putz, M., Lienkamp, S., Ganner, A., Bergbreiter, A., Ramachandran, H., Gieloff, V., Gerner, M., Mattonet, C., Czarnecki, P. G., Sayer, J. A., Otto, E. A., Hildebrandt, F., Kramer-Zucker, A., Walz, G.]]></dc:creator>
<dc:date>Tue, 06 Oct 2009 08:13:24 PDT</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp387</dc:identifier>
<dc:title><![CDATA[Genetic and physical interaction between the NPHP5 and NPHP6 gene products]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>21</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4226</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4226</prism:startingPage>
<prism:section>ERRATUM</prism:section>
</item>

</rdf:RDF>